DATE: October 7, 2010

SUBJECT: Chemicals Evaluated for Carcinogenic Potential by the Office of Pesticide Programs

FROM: Brenda May, Chief Science Information Management Branch Health Effect Division (7509P) Office of Pesticide Programs

TO: Division Directors AD, BPPD, EFED, FEAD, HED, RD and PRD

The attached list provides an overview of chemicals evaluated for carcinogenic potential by the Health Effects Division (HED) of the Office of Pesticide Programs (OPP) through August 2010. Applying the Agency's Guidelines for Carcinogen Risk Assessment, the classification of the chemical is made by HED's Cancer Assessment Review Committee (CARC) or, in the case of where there is no evidence of carcinogenicity, by the HED Risk Assessment Team.

This list includes the chemical name, CAS Number, PC code, the cancer classification, report date, species, tumor types, and, if required, the human equivalency potency factor (Q_1^*) . The potency factor (Q_1^*) , unless otherwise indicated, is based on the oral route. The Q_1^* is expressed as $(mg/kg/day)^{-1}$ for the oral route and as $(mg/m^3)^{-1}$ for the inhalation route.

It should be noted that the evaluation of many of these chemicals is an ongoing process, therefore, the information in this list (i.e., classification and/or the quantification) may be subject to change as new and/or additional data are submitted to OPP. This list should not be used as the single source for either the classification or quantification of the carcinogenic potential. This list will be updated annually.

If further information is required please contact me (Phone: 703-308-6175; E-mail: may.brenda@epa.gov).

Science Information Management Branch
Health Effects Division
Office of Pesticide Programs
U.S. Environmental Protection Agency

BACKGROUND

What is this list?

The Chemicals Evaluated for Carcinogenic Potential provides an overview of the compounds evaluated for carcinogenicity by the Health Effects Division of the Office of Pesticide Programs.

NOTE: As new information becomes available, the list may become out-of-date. Therefore, it should not be used as the sole reference regarding the carcinogenic potential for a pesticide. EPA intends to update the list each year to include new evaluations or re-evaluations.

How does EPA review pesticides for potential carcinogenicity?

The Health Effects Division of the Office of Pesticide Programs performs an independent review of studies conducted in mice and rats to evaluate the carcinogenic potential of pesticides. The results of the independent review are peer-reviewed by the Cancer Assessment Review Committee. This committee recommends a cancer classification. The classification will determine how the Agency regulates the pesticide and will include methods for quantification of human risk. In some cases, EPA also requests review by the FIFRA Scientific Advisory Panel.

What factors does EPA consider in its review of cancer risk?

When assessing possible cancer risk posed by a pesticide, EPA considers how strongly carcinogenic the chemical is (its potency) and the potential for human exposure. The pesticides are evaluated not only to determine if they cause cancer in laboratory animals, but also as to their potential to cause human cancer. For any pesticide classified as a potential carcinogen, the risk would depend on the extent to which a person might be exposed (how much time and to what quantity of the pesticide). The factors considered include short-term studies, long-term cancer studies, mutagenicity studies, and structure activity concerns. (The term "weight-of-the-evidence" is used in referring to such a review. This means that the recommendation is not based on the results of one study, but on the results of all studies that are available.)

When does EPA review pesticides for potential carcinogenicity?

EPA reviews studies submitted when a pesticide is proposed for registration. Studies are required in two species (mice and rats) and two sexes (males and females). These studies are required for all pesticides used on food and some non-food pesticides that could lead to long-term exposures in humans. These studies may be reviewed again when a pesticide undergoes reregistration and the cancer classification may be reevaluated, particularly if new studies have been submitted.

Why are there several different cancer classifications in the list?

EPA's guidelines for evaluating the potential carcinogenicity of chemicals have been updated over the years to reflect increased understanding of ways chemicals may cause cancer. The current guidelines call for greater emphasis on characterization discussions for hazard, doseresponse assessment, exposure assessment, and risk characterization, as well as the use of mode of action in the assessment of potential carcinogenesis.

EPA does not have the resources to re-evaluate every chemical to determine how it would be described under new guidelines, and there is no reason to re-evaluate chemicals unless there is some new information that could change the basic understanding of that chemical.

How have the guidelines changed?

EPA issued its first set of principles to guide evaluation of human cancer potential in1976. In 1986, EPA issued updated guidance, which included a letter system (A-E) for designating degree of carcinogenic potential. In the 1986 guidelines, hazard identification and the weight-of evidence process focused on tumor findings. The human carcinogenic potential of agents was characterized by a six-category alphanumeric classification system (A, B1, B2, C, and D). In 1996, EPA released "Proposed Guidelines for Carcinogen Risk Assessment," which used descriptive phrases rather than the alphanumeric classification to classify carcinogenic potential. In the 1996 classification structure, increased emphasis was placed on discussing characterization of hazard, dose-response, and exposure assessments. The hazard and weight of evidence process embraced an analysis of all relevant biological information and emphasized understanding the agent's mode of action in producing tumors to reduce the uncertainty in describing the likelihood of harm. By 1999, the science related to carcinogens had advanced significantly. EPA issued draft guidelines that continued the greater emphasis on characterization discussions for hazard, dose-response assessment, exposure assessment, risk characterization and the use of mode of action in the assessment of potential carcinogenesis. In addition, the guidelines included consideration of risk to children, as well as addressing other issues such as nuances related to the amount and adequacy of data on a chemical.

In March, 2005, EPA released its final *Guidelines for Carcinogen Risk Assessment* (EPA/630/P-03/001B). These guidelines represent the culmination of a long development process, replacing EPA's original cancer risk assessment guidelines (1986) and its interim final guidelines (1999). http://www.epa.gov/cancerguidelines/

How do the different designations compare?

The short answer is that they cannot be directly compared. Each system designation refers to the reviews and criteria it contains. A substance that is, for example, a "C" in the 1986 system may not be directly translatable to any particular category in the later systems. The designation for any substance must be considered in the context of the system under which it was reviewed.

A list of the descriptors from the various classification systems and their definitions are given on the following pages.

Carcinogenicity Classification of Pesticides: Derivation and Definition of Terms

CLASSIFICATION-2005

The following descriptors from the 2005 Guidelines for Carcinogen Risk Assessment can be used as an introduction to the weight of evidence narrative in the cancer risk assessment. The examples presented in the discussion of the descriptors are illustrative. The examples are neither a checklist nor a limitation for the descriptor. The complete weight of evidence narrative, rather than the descriptor alone, provides the conclusions and the basis for them.

CARCINOGENIC TO HUMANS. This descriptor indicates strong evidence of human carcinogenicity. It covers different combinations of evidence.

- This descriptor is appropriate when there is convincing epidemiologic evidence of a causal association between human exposure and cancer.
- Exceptionally, this descriptor may be equally appropriate with a lesser weight of epidemiologic evidence that is strengthened by other lines of evidence. It can be used when all of the following conditions are met: (a) there is strong evidence of an association between human exposure and either cancer or the key precursor events of the agent's mode of action but not enough for a causal association, and (b) there is extensive evidence of carcinogenicity in animals, and (c) the mode(s) of carcinogenic action and associated key precursor events have been identified in animals, and (d) there is strong evidence that the key precursor events that precede the cancer response in animals are anticipated to occur in humans and progress to tumors, based on available biological information. In this case, the narrative includes a summary of both the experimental and epidemiologic information on mode of action and also an indication of the relative weight that each source of information carries, e.g., based on human information, and based on limited human and extensive animal experiments.

LIKELY TO BE CARCINOGENIC TO HUMANS. This descriptor is appropriate when the weight of the evidence is adequate to demonstrate carcinogenic potential to humans but does not reach the weight of evidence for the descriptor "Carcinogenic to Humans." Adequate evidence consistent with this descriptor covers a broad spectrum. As stated previously, the use of the term "likely" as a weight of evidence descriptor does not correspond to a quantifiable probability. The examples below are meant to represent the broad range of data combinations that are covered by this descriptor; they are illustrative and provide neither a checklist nor a limitation for the data that might support use of this descriptor.

Moreover, additional information, e.g., on mode of action, might change the choice of descriptor for the illustrated examples. Supporting data for this descriptor may include:

 an agent demonstrating a plausible (but not definitively causal) association between human exposure and cancer, in most cases with some supporting biological, experimental evidence, though not necessarily carcinogenicity data from animal experiments;

- an agent that has tested positive in animal experiments in more than one species, sex, strain, site, or exposure route, with or without
 evidence of carcinogenicity in humans;
- a positive tumor study that raises additional biological concerns beyond that of a statistically significant result, for example, a high degree of malignancy, or an early age at onset;
- a rare animal tumor response in a single experiment that is assumed to be relevant to humans; or
- a positive tumor study that is strengthened by other lines of evidence, for example, either plausible (but not definitively causal)
 association between human exposure and cancer or evidence that the agent or an important metabolite causes events generally known
 to be associated with tumor formation (such as DNA reactivity or effects on cell growth control) likely to be related to the tumor response
 in this case.

SUGGESTIVE EVIDENCE OF CARCINOGENIC POTENTIAL. This descriptor of the database is appropriate when the weight of evidence is suggestive of carcinogenicity; a concern for potential carcinogenic effects in humans is raised, but the data are judged not sufficient for a stronger conclusion. This descriptor covers a spectrum of evidence associated with varying levels of concern for carcinogenicity, ranging from a positive cancer result in the only study on an agent to a single positive cancer result in an extensive database that includes negative studies in other species. Depending on the extent of the database, additional studies may or may not provide further insights. Some examples include:

- a small, and possibly not statistically significant, increase in tumor incidence observed in a single animal or human study that does not
 reach the weight of evidence for the descriptor "Likely to Be Carcinogenic to Humans." The study generally would not be contradicted by
 other studies of equal quality in the same population group or experimental system (see discussions of conflicting evidence and differing
 results, below);
- a small increase in a tumor with a high background rate in that sex and strain, when there is some but insufficient evidence that the observed tumors may be due to intrinsic factors that cause background tumors and not due to the agent being assessed. (When there is a high background rate of a specific tumor in animals of a particular sex and strain, then there may be biological factors operating independently of the agent being assessed that could be responsible for the development of the observed tumors.) In this case, the reasons for determining that the tumors are not due to the agent are explained;
- evidence of a positive response in a study whose power, design, or conduct limits the ability to draw a confident conclusion (but does not
 make the study fatally flawed), but where the carcinogenic potential is strengthened by other lines of evidence (such as structure-activity
 relationships); or
- a statistically significant increase at one dose only, but no significant response at the other doses and no overall trend.

INADEQUATE INFORMATION TO ASSESS CARCINOGENIC POTENTIAL. This descriptor of the database is appropriate when available data are judged inadequate for applying one of the other descriptors. Additional studies generally would be expected to provide further insights. Some examples include:

- little or no pertinent information;
- conflicting evidence, that is, some studies provide evidence of carcinogenicity but other studies of equal quality in the same sex and strain are negative. Differing results, that is, positive results in some studies and negative results in one or more different experimental

- systems, do not constitute *conflicting evidence*, as the term is used here. Depending on the overall weight of evidence, differing results can be considered either suggestive evidence or likely evidence; or
- negative results that are not sufficiently robust for the descriptor, "Not Likely to Be Carcinogenic to Humans."

NOT LIKELY TO BE CARCINOGENIC TO HUMANS. This descriptor is appropriate when the available data are considered robust for deciding that there is no basis for human hazard concern. In some instances, there can be positive results in experimental animals when there is strong, consistent evidence that each mode of action in experimental animals does not operate in humans. In other cases, there can be convincing evidence in both humans and animals that the agent is not carcinogenic. The judgment may be based on data such as:

- animal evidence that demonstrates lack of carcinogenic effect in both sexes in well-designed and well-conducted studies in at least two
 appropriate animal species (in the absence of other animal or human data suggesting a potential for cancer effects),
- convincing and extensive experimental evidence showing that the only carcinogenic effects observed in animals are not relevant to humans,
- convincing evidence that carcinogenic effects are not likely by a particular exposure route (see Section 2.3), or
- convincing evidence that carcinogenic effects are not likely below a defined dose range.

A descriptor of "not likely" applies only to the circumstances supported by the data. For example, an agent may be "Not Likely to Be Carcinogenic" by one route but not necessarily by another. In those cases that have positive animal experiment(s) but the results are judged to be not relevant to humans, the narrative discusses why the results are not relevant.

MULTIPLE DESCRIPTORS. More than one descriptor can be used when an agent's effects differ by dose or exposure route. For example, an agent may be "Carcinogenic to Humans" by one exposure route but "Not Likely to Be Carcinogenic" by a route by which it is not absorbed. Also, an agent could be "Likely to Be Carcinogenic" above a specified dose but "Not Likely to Be Carcinogenic" below that dose because a key event in tumor formation does not occur below that dose.

CLASSIFICATION -1999 Draft

The terms used to describe carcinogenic potential in the July 1999 "Review Draft of the Guidelines for Carcinogen Risk Assessment" are listed and defined as follows:

CARCINOGENIC TO HUMANS. This descriptor is appropriate when there is convincing epidemiologic evidence demonstrating causality between human exposure and cancer. This descriptor is also appropriate when there is an absence of conclusive epidemiologic evidence to clearly establish a cause and effect relationship between human exposure and cancer, but there is compelling evidence of carcinogenicity in animals and mechanistic information in animals and humans demonstrating similar mode(s) of carcinogenic action. It is used when all of the following conditions are met:

- There is evidence in a human population(s) of association of exposure to the agent with cancer, but not enough to show a causal association, and
- There is extensive evidence of carcinogenicity, and
- The mode(s) of carcinogenic action and associated key events have been identified in animals, and
- The keys events that precede the cancer response in animals have been observed in the human population(s) that also shows evidence of an association of exposure to the agent with cancer.

LIKELY TO BE CARCINOGENIC TO HUMANS. This descriptor is appropriate when the available tumor effects and other key data are adequate to demonstrate carcinogenic potential to humans. Adequate data are within a spectrum. At one end is evidence for an association between human exposure to the agent and cancer and strong experimental evidence of carcinogenicity in animals; at the other, with no human data, the weight of experimental evidence shows animal carcinogenicity by a mode or modes of action that are relevant or assumed to be relevant to humans.

SUGGESTIVE EVIDENCE OF CARCINOGENICITY, BUT NOT SUFFICIENT TO ASSESS HUMAN CARCINOGENIC POTENTIAL. This descriptor is appropriate when the evidence from human or animal data is suggestive of carcinogenicity, which raises a concern for carcinogenic effects but is judged not sufficient for a conclusion as to human carcinogenic potential. Examples of such evidence may include: a marginal increase in tumors that may be exposure-related, or evidence is observed only in a single study, or the only evidence is limited to certain high background tumors in one sex of one species. Dose-response assessment is not indicated for these agents. Further studies would be needed to determine human carcinogenic potential.

DATA ARE INADEQUATE FOR AN ASSESSMENT OF HUMAN CARCINOGENIC POTENTIAL. This descriptor is used when available data are judged inadequate to perform an assessment. This includes a case when there is a lack of pertinent or useful data or when existing evidence is conflicting, e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm a concern.

NOT LIKELY TO BE CARCINOGENIC TO HUMANS. This descriptor is used when the available data are considered robust for deciding that there is no basis for human hazard concern. The judgment may be based on:

- Extensive human experience that demonstrates lack of carcinogenic effect (e.g., phenobarbital).
- Animal evidence that demonstrates lack of carcinogenic effect in at least two well- designed and well-conducted studies in two
 appropriate animal species (in the absence of human data suggesting a potential for cancer effects).
- Extensive experimental evidence showing that the only carcinogenic effects observed in animals are not considered relevant to humans (e.g., showing only effects in the male rat kidney due to accumulation of alpha_{2u}-globulin).
- Evidence that carcinogenic effects are not likely by a particular route of exposure.
- Evidence that carcinogenic effects are not anticipated below a defined dose range.

CLASSIFICATION-1996

In April 1996, EPA released the "Proposed Guidelines for Carcinogen Risk Assessment." This scheme varied from the earlier 1986 scheme in that it used descriptors rather than letters to classify carcinogenic potential. The descriptors are:

KNOWN/LIKELY. This category of descriptors is appropriate when the available tumor effects and other key data are adequate to convincingly demonstrate carcinogenic potential for humans.

CANNOT BE DETERMINED. This category of descriptors is appropriate when available tumor effects or other key data are suggestive or conflicting or limited in quantity and, thus, are not adequate to convincingly demonstrate carcinogenic potential for humans. In general, further agent specific and generic research and testing are needed to be able to describe human carcinogenic potential.

NOT LIKELY. This is the appropriate descriptor when experimental evidence is satisfactory for deciding that there is no basis for human hazard concern, as follows (in the absence of human data suggesting a potential for cancer effects).

CLASSIFICATION -1986

The following cancer classification scheme was first introduced in 1986. It was used until 1996.

GROUP A-HUMAN CARCINOGEN. This group is used only when there is sufficient evidence from epidemiologic studies to support a causal association between exposure to the agents and cancer.

GROUP B-PROBABLE HUMAN CARCINOGEN. This group includes agents for which the weight of evidence of human carcinogenicity based on epidemiologic studies is "limited" and also includes agents for which the weight of evidence of carcinogenicity based on animal studies is "sufficient." The group is divided into two subgroups. **Group B1** is reserved for agents for which there is limited evidence of

carcinogenicity from epidemiologic studies. **Group B2** is used for Agents for which there is "sufficient: evidence from animal studies and for which there is "inadequate evidence" or "no data" from epidemiologic studies.

GROUP C-POSSIBLE HUMAN CARCINOGEN. This group is used for agents with limited evidence of carcinogenicity in animals in the absence of human data.

GROUP D-NOT CLASSIFIABLE AS TO HUMAN CARCINOGENICITY. This group is generally used for agents with inadequate human and animal evidence of carcinogenicity or for which no data are available.

GROUP E-EVIDENCE OF NON-CARCINOGENICITY FOR HUMANS. This group is used for agents that show no evidence for carcinogenicity in at least two adequate animal tests in different species or in both adequate epidemiologic and animal studies.

OTHER DEFINITIONS

Quantification of Cancer Risk - Carcinogenic Potency Factor (Q₁*)

Q1 STAR (Q1*) - In the classification of human or probable-human carcinogens, mathematical models are used to estimate an upper-bound excess cancer risk associated with lifetime ingestion in the diet. The data used in these estimates usually come from lifetime exposure studies in animals. The USEPA generally uses the linearized multistage model for its cancer risk assessment. This model fits linear dose-response curves to low doses and is consistent with a no-threshold model of carcinogenesis, i.e., exposure to even a very small amount of the substance produces a finite increased risk of cancer.

The linearized multistage model uses dose-response data from the most appropriate carcinogenic study to calculate a carcinogenic potency factor (q₁*) for humans. The q₁* is then used to determine the concentrations of the chemical in the diet that are associated with theoretical upperbound excess lifetime cancer risks of 1 in 10,000, 1 in 100,000, and 1 in 1,000,000 (10-4, 10-5, 10-6 respectively) individuals over a lifetime of exposure.

Mode of Action (MOA) - The key cellular and biochemical events that have to happen for a biological effect to develop. Mode of action is contrasted with mechanism of action which is a more complete understanding of the step by step pathway leading to a biological effect. Some established MOAs include:

Androgen Dependent - The chemical disrupts the normal levels of reproductive hormones (e.g., testosterone, luteinizing hormone) which in turn stimulates the target tissue (e.g., leydig cells, testicular tissue) to divide which may lead to hyperplasia and neoplasia. For agents to pose a hazard to humans by this MOA, sufficient exposure levels need to be encountered which produce the same level of biological effect as seen in rodents. This is consistent with the MOA for Leydig cell tumorigenesis.

Cytotoxicity and Regenerative Proliferation - Continuous exposure to a chemical or its metabolite causes persistent cell killing which in turn may result in a persistent regenerative proliferative response in the damaged tissue. For irreversible tissue alterations to occur in humans, including cancer by this mode of action, a sufficient exposure must be encountered over a prolonged period.

Mitogenesis - Mitogenic chemicals act by promoting the clonal expansion of preneoplastic cells by stimulating cell proliferation. This mode of action is frequently found in the rodent liver where it is generally associated with an increase in metabolizing enzymes. A mitogenic chemical stimulates cell proliferation in the target organ without obvious cytotoxicity or cell death. Another important feature of this MOA is that the mitogenic effect is not persistent over time; instead it is resolved and then is manifested within proliferative foci which are considered preneoplastic lesions. Through continuous exposure, it is these preneoplastic lesions that develop into tumors. At this time, the adverse health effects caused by this MOA are presumed to be relevant to humans.

Mutagenesis - The chemical or a metabolite has the ability to react with or bind DNA in a manner that causes mutations. It is usually positive in multiple test systems for different genetic endpoints (particularly gene mutations and structural chromosome aberrations) and in tests performed *in vivo* and *in vitro*. Adverse health effects in rodents from these chemicals are considered relevant for human health risk.

Neuroendrocrine Disruption - Chemicals that disrupt hypothalamic control of pituitary function leading to a decrease in hormone release (e.g., luteinizing hormone) and the disruption of the ovarian cycle. This may result in an increase in cell proliferation in the mammary gland due to a hyperstimulation by estrogen. In the case of chloro-s-triazines, this neuroendocrine MOA is not considered relevant to humans because it depends on a rodent specific reproductive process.

PPAR-alpha Agonism - Chemicals that bind to and activate the Peroxisome Proliferator-Activated Receptor (PPAR) stimulate biological responses in the liver (e.g., peroxisome proliferation, induction of lipid metabolizing enzymes, oxidative stress, and hepatocyte mitogenesis). Activation of PPAR-alpha results in an increase in cell proliferation and clonal expansion of preneoplastic foci in the liver. While the human relevance of this MOA has not been definitively determined, most of the evidence indicates that this mode of action is not operative in the human liver.

Thyroid Hormone Disruption - Disruption of normal levels of thyroid hormones may lead to an increase of thyroid stimulating hormone (TSH) which results in an increase in cell proliferation of the thyroid gland. If exposure is continuous in the animal, thyroid follicular cell tumors can potentially develop. However, the development of thyroid cancer by this mode of action in humans is considered unlikely since prolonged stimulation of the thyroid gland by TSH has not been associated with tumorigenesis in humans. However, this MOA is relevant as an indicator for potential noncancer health effects (e.g., goiter, neurodevelopmental, etc) due thyroid disruption in humans.

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT	QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Nati itali da Ba Cantina da	DATE	METHOD	
4.0 Fellow 5 and H. India	00445.07.0	400000	Not Likely to Be Carcinogenic	OPP	ND	NI-CAPII-
1,3-dichloro-5-methylhydantoin	89415-87-2	128826	to Humans	(8/28/00)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
2, 4 - DBA	94-82-6	030801	to Humans	(6/13/03)	NR	Not Applicable
	1		Group DNot Classifiable as to			
2,4-D + Salts & Esters	94-75-7	030001	Human Carcinogenicity	(1/29/97)	NR	Not Applicable
			Group CPossible Human	OPP		Renal tubule combined adenomas/carcinomas; B6C3F1 mice
2-Benzyl-4-chlorophenol	120-32-1	062201	Carcinogen	(9/5/95)	RfD Approach	(M). Renal transitional cell carcinomas; F344/N rats (F)
			Group DNot Classifiable As			
4-aminopyridine	504-24-5	069201	To Human Carcinogenicity	8/6/2007	NR	Not Applicable
			Group CPossible Human	OPP		
Acephate	30560-19-1	103301	Carcinogen	(5/8/85)	NR	Hepatocellular carcinomas; CD-1 mice (F)
			Not Likely to De Careina genie	OPP		
Accessing	E7000 40 7	006329	Not Likely to Be Carcinogenic to Humans		NR	Not Applicable
Acequinocyl	57960-19-7	006329		(11/13/03)	INK	Not Applicable
Acatamida	00.05.5	444404	Group CPossible Human	OPP	ND	Liver towns and Mistor anto (MA), FOAA anto (MA 9, F)
Acetamide	60-35-5	111101	Carcinogen	(5/29/90)	NR	Liver tumors; Wistar rats (M); F344 rats (M & F).
			Net Libebate De Considerantie	ODD		
A	105110 00 7	000050	Not Likely to Be Carcinogenic	OPP	ND	NI-CAPII-
Acetamiprid	135410-20-7	099050	to Humans	(12/11/01)	NR	Not Applicable
	0.4050.00.4	101001	Suggestive Evidence of	OPP	D(D 4	Benign pulmonary adenomas (M & F) and ovarian histiocytic
Acetochlor	34256-82-1	121601	Carcinogenic Potential	(6/30/04)	RfD Approach	sarcomas (F) CD-1 mice
	1		Not Likely to Be Carcinogenic	OPP		
Acibenzolar-S-methyl	135158-54-2	061402	to Humans	(12/9/99)	NR	Not Applicable
			Multiple Descriptors: Likely to			
			be Carcinogenic to Humans at			
			High Doses Not Likely to be			
			Carcinogenic to Humans at	OPP		
Acifluorfen sodium	62476-59-9	114402	Low Doses	(5/21/03)	MOE Approach	Liver; B6C3F1 & CD-1 mice (M & F).
			Group DNot Classifiable as to	OPP		
Acrinathrin	101007-06-1	129141	Human Carcinogenicity	(7/15/96)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
ADBAC	68424-85-1	069105	to Humans	-	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE			QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
Alachlor	15972-60-8	090501	Multiple Descriptors: Likely to be Carcinogenic to Humans (High Doses); Not Likely to be Carcinogenic to Humans (Low Doses)	OPP (6/27/97)	MOE Approach	Increased incidences of malignant & combined benign/malignant multiple tumor types in both sexes; Long Evans rat
	1.00.2 00 0		Group EEvidence of Non-	OPP)		
Aldicarb	116-06-3	098301	carcinogenicity for Humans	(9/15/98)	NR	Not Applicable
Ametryn	834-12-8	080801	Data Are Inadequate for an Assessment of Human Carcinogenic Potential Not Likely To Be Carcinogenic		NR	Not Applicable
Amicarbazone	129909-90-6	114004	To Humans	8/10/2005	NR	Not Applicable
Aminocyclopyrachlor	858956-35-1, 858954-83-3,	288008	Not Likely To Be Carcinogenic To Humans	3/17/2010	NR	Not applicable
Aminopyralid	150114-71-9	005100	Not Likely To Be Carcinogenic To Humans	10/22/2009	NR	Not Applicable
Amitraz	33089-61-1	106201	Suggestive Evidence of Carcinogenic Potential	OPP (10/31/90)	NR	Lymphoreticular tumors; CFLP mice (F). Hepatocellular adenomas, carcinomas & adenomas/carcinomas combined; B6C3F1 mice (F); Lung adenomas; B6C3F1 mice (M).
Amitrole	61-82-5	004401	Multiple Descriptors: Not Likely To Be Carcinogenic To Humans At Doses That Do Not Alter Rat Thyroid Hormone Homeostasis	OPP (8/20/90)	NR	Thyroid, liver & pituitary tumors in Charworth Farms, Fischer 344 & Wistar rats (M & F). Liver & thyroid tumors in B6C3F1 & NMRI mice (M & F). Anti-thyroid MOA.
Annahada	0050 40 0	110001	Not Likely To Be Carcinogenic		ND	
Aquashade	2650-18-2	110301	To Humans Group CPossible Human	9/27/2005 OPP	NR	Not Applicable Malignant thyroid C-cell tumors; Benign adrenal
Asulam	3337-71-1	106901	Carcinogen	1 -	NR	pheochromocytomas; Sprague-Dawley rats (M).
Atrazine	1912-24-9	080803	Not Likely to be Carcinogenic to Humans	OPP (12/13/00)	NR	Mammary tumors; Sprague-Dawley rats (F). Neuroendocrine Distruption MOA.
Avermectin (see Emamectin Benzoate)	65195-55-3	122804	Group EEvidence of Non-carcinogenicity for humans	OPP (6/27/96	NR	Not Applicable
,			Data Are Inadequate for an Assessment of Human	OPP		
Azafenidin	68049-83-2	119016	Carcinogenic Potential	(10/18/99)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Not Likely to Be Carcinogenic	OPP		
Azinphos-methyl	86-50-0	058001	to Humans	(12/7/93)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Azoxystrobin	131860-33-8	128810	to Humans	(1/14/97)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Bendiocarb	22781-23-3	105201	carcinogenicity for Humans	(12/16/97)	NR	Not Applicable
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		
Benfluralin	1861-40-1	084301	Carcinogenic Potential	(12/27/01)	NR	Liver tumors in female B6C3F1 mice
			Group CPossible Human	OPP		Liver tumors (hepatocellular adenomas & carcinomas) in 2
Benomyl	17804-35-2	099101	Carcinogen	(09/21/00)	Q1* = 2.39 E-3 (3/4)	genetically related strains of mice (CD-1 & Swiss SPF) (M & F)
			Not Likely to Be Carcinogenic	OPP		
Bensulide	741-58-2	009801	to Humans	(6/10/97)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Bentazon	25057-89-0	275200	carcinogenicity for Humans	(11/10/93)	NR	Not Applicable
						Liver tumors (M &F); thyroid follicular cell tumors (M) in
			Likely to be Carcinogenic to			B6C3F1 Mice
Benthiavalicarb-isopropyl	177406-68-7	098379	Humans		Q1* = 6.2795 E-2 (3/4)	Malignant uterine tumors (F) in Fisher 344 Rat
			Not Likely To Be Carcinogenic			
Beta Cyfluthrin	68359-37-5	118831	To Humans	1/27/2010	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Bifenazate	149877-41-8	000586	to Humans	(8/28/01)	NR	Not Applicable
						Hemangiopericytomas in the urinary bladder; Hepatocellular
			Group CPossible Human	OPP		carcinomas & combinded hepatocellular adenomas &
Bifenthrin	82657-04-3	128825	Carcinogen	(4/29/92)	RfD Approach	carcinomas; Swiss Webster mice (M)
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		Renal tubular adenomas in male Sprague-Dawley Crl-CD-
Bioallethrin	584-79-2	004003	Carcinogenic Potential	(10/29/03)	NR	SD(BR) rats
			Not Likely to Be Carcinogenic	OPP		
Bispyrabac Sodium	125401-92-5	078906	to Humans	(8/2/01)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Bitertanol	55179-31-2	117801	To Humans	11/30/2005	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Borax	1303-96-4	011102	carcinogenicity for humans	(11/24/93)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION		QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group EEvidence of Non-	OPP		
Boric acid	10043-35-3	011001	carcinogenicity for humans	(11/24/93)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Boron	7440-42-8	128945	carcinogenicity for humans	(11/24/93)	NR	Not Applicable
			Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human	OPP		
Boscolid	188425-85-6	128008	Carcinogenic Potential	(9/25/02)	NR	Thyraid followlar call adaptages, male and famale Wister rate
Boscolia	188425-85-6	128008	Carcinogenic Potentiai	(9/25/02)	INK	Thyroid follicular cell adenomas, male and female Wistar rats.
Bromacil	314-40-9	012301	Group CPossible Human Carcinogen	OPP (1/13/93)	RfD Approach	Liver tumors (carcinomas & combined adenomas/carcinomas); CD-1 mice (M). Thyroic tumors (C-cell adenomas & follicular cell combined adenomas/carcinomas); Crl:CD (BR) rats (M).
			Group CPossible Human	OPP		Statistically significant increases in hepatocellular adenomas and/ or carcinomas and combined adenomas/carcinomas; CD-
Bromoxynil	1689-84-5	035301	Carcinogen	(3/12/97)	Q1* = 1.03 E-1 (3/4)	1 mice (M & F).
			Group EEvidence of Non-	OPP		
Bromuconazole	116255-48-2	120503	carcinogenicity for humans	(4/24/95)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Bronopol	52-51-7	216400	carcinogenicity for humans	(6/16/95)	NR	Not Applicable
Buprofezin	69327-76-0	275100	Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential	OPP (3/15/00)	NR	Significant increase by pair-wise comparison w/the controls for combined hepatocellular adenomas/carcinomas in females; CD-1 mice
Butachlor	23184-66-9	112301	Likely to be Carcinogenic to Humans	OPP (2/26/99)	NR	Multiple tumors in multiple sites in Sprague-Dawley rats including rare stomach tumors in F, rare kidney tumors in M & F, as well as tumors of the nasal mucosa and thyroid glands in M & F.
			Not Likely to Be Carcinogenic	OPP		
Butafenacil	134605-64-4	122004	to Humans	(7/11/03)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Butylate	2008-41-5	041405	carcinogenicity for humans	(11/25/92)	NR	Not Applicable
Cacodylic acid	75-60-5	012501	Group BProbable Human Carcinogen	OPP (12/14/99)	Q1* = 6.23 E-2 (3/4)	Urinary bladder tumor; Fischer 344 rats (M & F). Fibrosarcomas (multiple organs); B6C3F1 mice (F). This chemical is currently under Agency re-review.
	. 5 55 5	3.2001	Group EEvidence of Non-	OPP	Δ 0.20 L L (0/4)	strong and regards to to to the strong and a strong a strong and a strong a strong a strong and a strong
Cadusafos	95465-99-9	128864	carcinogenicity for humans		NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
Captafol	2939-80-2	081701	Group BProbable Human Carcinogen	OPP (5/15/89)	Q1* = 5.1 E-2 (2/3)	Lymphosarcomas & hemangiosarcomas (M & F), harderian gland adenomas (M) CD-1 mice. Mammary fibroadenoma (M & F), renal adenomas/carcinomas (combined) (M); Sprague-Dawley rats (M).
Captan	133-06-2	081301	Multiple Descriptors: Likely at prolonged, high-level exposures, but not likely at dose levels that do not cause cytotoxicity and regenerative cell hyperplasia	OPP (9/4/98)	NR	Intestinal adenomas and adenocarcinomas in CD-1 mice (M & F).
Carbaryl	63-25-2	056801	Likely to be Carcinogenic to Humans	OPP (2/12/02)	Q1* = 8.75 E-4 (3/4)	Hemangiosarcomas (malignant vascular tumors) & combined hemagiomas/ hemangiosarcomas; CRL:CD-1 (ICR)BR mice (M).
Carbendazim (MBC)	10605-21-7	128872	Group CPossible Human Carcinogen	OPP (4/7/89)	Q1* = 2.39 E-3 (3/4)	genetically related strains of mice (CD-1 & Swiss SPF) (M & F).
Carbofuran	1563-66-2	090601	Not Likely to Be Carcinogenic to Humans	OPP (6/17/97)	NR	Not Applicable
Carboxin	5234-68-4	090201	Not Likely to Be Carcinogenic to Humans	OPP (6/5/03)	NR	Not Applicable
Carfentrazone-ethyl	128639-02-1	128712	Not Likely to Be Carcinogenic to Humans	OPP (3/24/98)	NR	Not Applicable
Chlorantraniliprole	500008-45-7	090100	Not Likely To Be Carcinogenic To Humans	1/20/2010	NR	Not Applicable
Chlordimeform	6164-98-3	059701	Group BProbable Human Carcinogen	OPP (12/20/85)	Q1* = 1.29 E-1 (3/4)	Malignant hemangioendothelomas; Tif:MAG:SPF mice (M & F).
Chlorethoxyfos	54593-83-8	129006	Group DNot Classifiable as to Human Carcinogenicity	(3/9/95)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Suggestive Evidence of			Liver tumors (adenomas and combined
			Carcinogenicity, but Not			adenomas/carcinomas, due mainly to adenomas), malignant
			Sufficient to Assess Human	OPP		histiocytic sarcomas, and testicular cell tumors in male rats
Chlorfenapyr	122453-73-0	129093	Carcinogenic Potential	(3/18/03)	NR	and uterine polyps in female rats
			Not Likely To Be Carcinogenic			
Chlorimuron-ethyl	90982-32-4	128901	To Humans	9/14/2009	NR	Not Applicable
Chloroaniline, p-	106-47-8	017203	Group BProbable Human Carcinogen	OPP (4/27/95)	Q1* = 1.12 E-1 (3/4)	Spleen (fibrosarcomas, hemangiosarcomas & osteosarcomas) (M); Adrenal (pheochromocytomas) (M & F); F344/N rats. Hepatocellular adenomas/carcinomas (M); Hemangiosarcomas in spleen and/or liver (M) in B6C3F1 mice.
.,,			Data Are Inadequate for an	,	. (3.)	
			Assessment of Human	OPP		
Chloroneb	2675-77-6	027301	Carcinogenic Potential	(12/18/03)	NR	Not Applicable
			Not Likely To Be Carcinogenic	ĺ .		
Chloropicrin	76-06-2	081501	To Humans		NR	Not Applicable
			Group BProbable Human	OPP		Renal adenomas & carcinomas, both sexes of rats & mice; rarity of the tumor response in the kidney; papillomas and/or carcinomas of the forestomach in rats & mice; CD-1 mice;
Chlorothalonil	1897-45-6	081901	Carcinogen	(10/27/97)	Q1* = 7.66 E-3 (3/4)	Fischer 344 & Osborne-Mendel rats.
O'llorotrialoriii	1007 40 0	001001	Group EEvidence of Non-	OPP	Q1 = 7.00 L 0 (0/4)	Tibolioi 644 & Cobolilo Molidoi fato.
Chlorpropham	101-21-3	018301	carcinogenicity for humans	(10/11/94)	NR	Not Applicable
- поприорилания	101210		Group EEvidence of Non-	OPP		Тем фринции
Chlorpyrifos	2921-88-2	059101	carcinogenicity for humans	(11/23/93)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Chlorpyrifos methyl	1351032	059102	to Humans	(5/17/99)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Chlorsulfuron	64902-72-3	118601	carcinogenicity for humans	(7/17/02)	NR	Not Applicable
Chlauth of direction (DCDA)	4004 20 4	070704	Group CPossible Human	OPP	04* 4.40 F.2 (2/4)	Thyroid tumors (M & F); Hepatocellular adenoma/carcinoma/hepato- choloangiocarcinoma (F); Sprague-Dawley rats. Hepatocellular adenomas & combined
Chlorthal-dimethyl (DCPA)	1861-32-1	078701	Carcinogen Not Likely To Be Carcinogenic	(2/10/95)	Q1* = 1.49 E-3 (3/4)	adenoma/carcinoma; CD-1 mice (F).
Clethodim	99129-21-2	121011	To Humans	2/24/2010	NR	Not Applicable
Cietilodiffi	99129-21-2	121011	TO FIGURES	2/24/2010	INIT	Prostate gland adenomas at high dose can not be discounted.
			Suggestive Evidence of	OPP		Peroxisome proliferation - activated receptor antagonism MOA
Clodinafop-propargyl	105512-06-9	125203	Carcinogenic Potential	(12/7/99)	NR	for liver tumors in mice.
Oloulialop-propargyi	100012-00-9	120200	Caroniogenio i Otentiai	(12/1/33)	1417	TOT HACE CHIHOLO III HIHOG.

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group CPossible Human	OPP		Statistically significant increase in histiocytic sarcomas (F); CD-
Clofencet (MON 21200)	82697-71-0	128726	Carcinogen	(7/23/96)	RfD Approach	1 mice.
			Group CPossible Human	OPP		Increased incidence of benign & malignant thyroid follicular cell
Clofentezine	74115-24-5	125501	Carcinogen	(4/3/90)	Q1* = 3.76 E -2 (3/4)	adenoma/carcinoma in male Sprague-Dawley rat
			Not Likely to Be Carcinogenic	OPP		
Clomazone	81777-89-1	125401	to Humans	(1/31/01)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Clopyralid	1702-17-6	117403	to Humans	(12/20/99)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Cloquintocet-mexyl	99607-70-2	700099	to Humans	(11/24/98)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Cloransulam-methyl	147150-35-4	129116	carcinogenicity for humans	(9/30/97)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Clothianidin	210880-92-5	044309	to Humans	(1/6/03))	NR	Not Applicable
			Likely to be Carcinogenic to	OPP		Liver adenomas, carcinomas hepatoblastomas; B6C3F1 mice
Cocamide Diethanolamine	68603-42-9	224600	Humans	(7/25/01)	Q1* = 4.01 E-1 (3/4)	(M & F) and kidney tumors (F)
			Not Likely to Be Carcinogenic	OPP		
Coumaphos	56-72-4	036501	to Humans	(6/25/99)	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
Cresol, p-Chloro-m-	59-50-7	064206	Human Carcinogenicity	(11/28/95)	NR	Not Applicable
·			Group DNot Classifiable as to	OPP		
Cryolite	15096-52-3	075101	Human Carcinogenicity	(1/26/93)	NR	Not Applicable
			Suggestive Evidence Of			
Cumyluron	99485-76-4	027902	Carcinogenic Potential	8/28/2008	NR	Liver adenomas in B6C3F1 Mouse (M & F)
			Group CPossible Human	OPP		Mammary gland tumors (adenocarcinoma, carcinosarcoma);
Cyanazine	21725-46-2	100101	Carcinogen	(7/30/91)	Q1* = 1.01 E-0 (2/3)	Sprague- Dawely rat (F).
			Not Likely To Be Carcinogenic			
Cyazofamid	120116-88-3	085651	To Humans	4/7/2010	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Cyclanilide	113136-77-9	026201	to Humans	(4/9/97)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Cycloate	1134-23-2	041301	to Humans	(9/25/03)	NR	Not Applicable
			Likely To Be Carcinogenic To	, , , , , , , , , , , , , , , , , , ,		
Cyflufenamid		555550	Humans		Q1* = 6.61 E -3 (3/4)	Thyroid Follicular Cell Crl:CD Rat (M); Liver CD-1 Mouse (M)
·			Not Likely to Be Carcinogenic	OPP		
Cyfluthrin	68359-37-5	128831	to Humans	(2/11/01)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION		QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
		T T	Not Likely To Be Carcinogenic			
Cyhalofop-butyl	122008-85-9	082583	To Humans	1/8/2009	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
Cyhalothrin	68085-85-8	128867	Human Carcinogenicity	(9/15/94)	NR	Not Applicable
			Data Are Inadequate for an			
			Assessment of Human	OPP		
Cyhexatin	13121-70-5	101601	Carcinogenic Potential	(8/1/00)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Cymoxanil	57966-95-7	129106	to Humans	(1/21/98)	NR	Not Applicable
						Benign lung adenomas (increase in both adenomas and
			Group CPossible Human	OPP		adenomas/ carcinomas combined); Alderly Park SPF Swiss
Cypermethrin	52315-07-8	109702	Carcinogen	(9/27/88)	NR	strain mice (F).
Сурсинский	32313 07 0	103702	Group BProbable Human	OPP	IVIX	Strain mice (i).
Cyproconazole	94361-06-5	128993	Carcinogen	(12/04/92)	Q1* = 1.58 E-1 (3/4)	Hepatocellular adenomas & carcinomas; CD-1 mice (M & F).
сур: «« — — — — — — — — — — — — — — — — — —	0.00.00	.2000	Not Likely to Be Carcinogenic	OPP	Q: ::00 = : (0, :)	inspands similar additional area can emission (in arry).
Cyprodinil	121552-61-2	288202	to Humans	(1/14/98)	NR	Not Applicable
	12.002.01.2		Not Likely To Be Carcinogenic	(.,, .,		The state of the s
			To Humans at doses that do			
			not cause urothelium			
Cyprosulfamide	221667-31-8	877400	cytotoxicity		NR	No applicable
- 71			Group EEvidence of Non-	OPP		
Cyromazine	66215-27-8	121301	carcinogenicity for humans	(1/6/95)	NR	Not Applicable
			j	,		
			Group BProbable Human	OPP		Multiple sites (eg. lungs, vessels, liver & kidney); Multiple
Daminozide	1596-84-5	035101	Carcinogen	-	Q1* = 8.7 E-3 (2/3)	species, strains & studies.
		000.0.	Not Likely to Be Carcinogenic	OPP	Q: 0:: 2 0 (2/0)	
Dantochlor (BCDMH)	118-52-5	028501	to Humans	(8/14/2000)	NR	Not Applicable
,				,		
			Group DNot Classifiable as to			
Dazomet	533-74-4	035602	Human Carcinogenicity	(12/7/93)	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
DEET	134-62-3	080301	Human Carcinogenicity	(1/4/96)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Deltamethrin	52918-63-5	097805	to Humans	(9/9/03)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
					211102	
			Group EEvidence of Non-	OPP		
Desmedipham	13684-56-5	104801	carcinogenicity for humans	(7/26/94)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Diazinon	333-41-5	057801	to Humans	(6/17/97)	NR	Not Applicable
			Group DNot Classifiable as to			
Dicamba	1918-00-9	029801	Human Carcinogenicity	(7/29/96)	NR	Not Applicable
						Adenomas alone & in combined adenoma/carcinoma at the
			Group CPossible Human	OPP		HDT only (F); Hepatocellular adenomas and carcinomas,
Dichlobenil	1194-65-6	027401	Carcinogen	(7/18/95)	RfD Approach	alone and combined (M & F); Fischer 344 rats.
			Not Likely To Be Carcinogenic			
Dichlormid	37764-25-3	900497	To Humans	11/15/2005	NR	Not Applicable
			Group DNot Classifiable as to			
Dichlorobenzamide, 2,6-	2008-88-4	027402	Human Carcinogenicity	(11/28/95)	NR	Not Applicable
			Suggestive Evidence of			
			Carcinogenicity, but Not			Mononuclear cell leukemia in male rats and forestomach
			Sufficient to Assess Human	OPP		tumors (squamous cell papilloma and/or carcinoma) in female
Dichlorvos	62-73-7	084001	Carcinogenic Potential	(3/1/00)	NR	mice.
			Likely to be Carcinogenic to	OPP		Liver tumors were seen in both sexes of two species including
Diclofop-methyl	51338-27-3	110902	Humans	(5/24/00)	Q1* = 7.36 E-2 (3/4)	both benign & malignant liver tumors in Wistar rats & B6C3F1
			Suggestive Evidence Of			
Dicloran	99-30-9	031301	Carcinogenic Potential	5/11/2006	NR	Testes Wistar (Hsd Cpb:WU) Rat (M)
			Not Likely to Be Carcinogenic	OPP		
Diclosulam	145701-21-9	129122	to Humans	(11/9/99)	NR	Not Applicable
			Group CPossible Human	OPP		
Dicofol	115-32-2	010501	Carcinogen	(4/15/92)	NR	Liver tumors (adenomas) in B6C3F1 mice (M)
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		Increasing trend for thyroid follicular cell adenomas; C57BL/10
Dicrotophos	141-66-2	035201	Carcinogenic Potential	(/	NR	J CD-1 Alpk mice (M & F)
Didecyl dimethyl ammonium			Group EEvidence of Non-	OPP		
chloride (DDAC)	7173-51-5	069149	carcinogenicity for Humans	(4/11/00)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
						Statistically significant increases in liver adenomas,
			Group CPossible Human	OPP		carcinomas & combined adenomas/carcinomas; CD-1 mice (M
Difenoconazole	119446-68-3	128847	Carcinogen	(7/27/94)	MOE Approach	& F).
			Group EEvidence of Non-	OPP		
Difenzoquat methyl sulfate	43222-48-6	106401	carcinogenicity for humans	(5/24/94)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Diflubenzuron	35367-38-5	108201	carcinogenicity for humans	(4/27/95)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Diflufenzopyr Sodiium	109293-98-3	005107	to Humans	(10/6/98)	NR	Not Applicable
						Statistically significant increasing trend for benign combined
						and/ or malignant liver tumors; Sprague-Dawley rat (M).
			Group CPossible Human	OPP		Unresolved issues regarding nasal tumors, strong
Dimethenamid	87674-68-8	129051	Carcinogen	(9/15/95)	RfD Approach	mutagenicity data & SAR.
			Group CPossible Human	OPP		
Dimethipin	55290-64-7	118901	Carcinogen	(1/5/90)	NR	Lung adenomas & carcinomas; CD-1 mice (M)
			Group CPossible Human	OPP		Hemolymphoreticular tumors; B6C3F1 mice (M). Spleen (hemangioma & hemangiosarcoma) skin (hemangiosarcoma),
Dimethoate	60-51-5	035001	Carcinogen	(8/29/91)	RfD Approach	lymph (angioma and angiosarcoma) tumors; Wistar rats (M).
			Not Likely to Be Carcinogenic	OPP		
Dimethomorph	110488-70-5	268800	to Humans	(5/11/98)	NR	Not Applicable
			Suggestive Evidence of	OPP		
Dimethoxane	828-00-2	001001	Carcinogenic Potential	(12/21/00)	NR	Neoplastic lesions in forestomach of mice
			Group DNot Classifiable as to			
Dimethyl ether	115-10-6	900382	Human Carcinogenicity	(1/12/94)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Dimethylhydantoin	16079-88-2	006315	to Humans	(8/28/00)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Dinocap	39300-45-3	036001	carcinogenicity for Humans	(6/22/94)	NR	Not Applicable
			Group CPossible Human	OPP		
Dinoseb	88-85-7	037505	Carcinogen	(6/19/86)	NR	Liver adenomas; CD-1 mice (F).
			Not Likely to Be Carcinogenic	OPP		
Dinotefuran	165252-70-0	044312	to Humans	(3/5/04)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Diphenylamine	122-39-4	038501	to Humans	(4/1/97)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Diquat dibromide	85-00-7	032201	carcinogenicity for Humans	(5/12/94)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Not Likely to Be Carcinogenic	OPP		
Disodium methanearsonate	144-21-8	013802	to Humans	(7/26/00)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Disulfoton	298-04-4	032501	carcinogenicity for Humans	(4/21/97)	NR	Not Applicable
Dithionon	22.47.22.6	000004	Suggestive Evidence of		ND	Kidney tumore (adenomos) in female rate
Dithianon	3347-22-6	099201	Carcinogenic Potential Group EEvidence of Non-	OPP	NR	Kidney tumors (adenomas) in female rats
Dithian (MON 7200)	07000 45 0	100004			ND	Not Applicable
Dithiopyr (MON 7200)	97886-45-8	128994	carcinogenicity for Humans	(10/13/93)	NR	Not Applicable
			Likely to be Caraine senie to	OPP		Urinary bladder carcinomas (M&F); Kidney carcinomas (M);
Diuron	330-54-1	035505	Likely to be Carcinogenic to Humans	(5/8/97)	O1* 1 01 E 2 (2/4)	Wistar rat (M & F). Mammary gland carcinomas; NMRI mice
Diuron	330-34-1	033303	Not Likely To Be Carcinogenic	(5/6/97)	Q1* = 1.91 E-2 (3/4)	(F)
Dodine	2439-10-3	044301	To Humans	1/24/2008	NR	Not Applicable
Dodine	2439-10-3	044301	Not Likely to Be Carcinogenic	OPP	INIX	Not Applicable
Ecolyst		069089	to Humans	(10/19/99)	NR	Not Applicable
Emamectin Benzoate (Deoxy		009009	Not Likely to Be Carcinogenic	OPP	INIX	Not Applicable
Avermectin)	137512-74-4	122806	to Humans	(3/19/98)	NR	Not Applicable
Avermecum	137312-74-4	122000	Not Likely to Be Carcinogenic	OPP	INIX	Not Applicable
Endosulfan	115-29-7	079401	to Humans	(1/31/00)	NR	Not Applicable
Liidosdiiaii	113-23-1	073401	Not Likely To Be Carcinogenic	(1/31/00)	INIX	Not Applicable
Endothall	145-73-3	038901	To Humans	11/9/2009	NR	Not Applicable
	106325-08-0,	000001	Likely to be Carcinogenic to	OPP		Combined hepatocellular tumors in male or female C57BL/6N
Epoxiconazole	133855-98-8	123909	Humans	(1/24/01)	Q1* = 3.04E-2 (3/4)	CrlBr mice.
	100000 00 0		Suggestive Evidence of Carcinogenicity, but Not	(,,=,,,,	0.0.12.2 (0, 1)	
			Sufficient to Assess Human	OPP		Renal tubular adenomas in male Sprague-Dawley Crl-CD-
Esbiothrin	28434-00-6	004007	Carcinogenic Potential	(10/29/03)	NR	SD(BR) rats
			Group EEvidence of Non-	OPP		
Esfenvalerate	66230-04-4	109303	carcinogenicity for Humans	(7/1/96)	NR	Not Applicable
						Treatment-related increase in only one tumor type (benign
			Suggestive Evidence of			Leydig cell tumors of the testes) in one species (Sprague
Ethaboxam	162650-77-03	090205	Carcinogenic Potential		NR	Dawley rat).
			Group CPossible Human	OPP		Mammary tumors (F); Suggestion of bladder tumors (F) and
Ethalfluralin	55283-68-6	113101	Carcinogen	(9/14/94)	Q1* = 8.9 E-2 (3/4)	kidney tumors (M & F); Fischer 344 rats
			Group DNot Classifiable as to	OPP		
Ethephon	16672-87-0	099801	Human Carcinogenicity	(5/5/94)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group EEvidence of Non-	OPP	INCTIOD	
Ethion	563-12-2	058401	carcinogenicity for humans	(1/26/94)	NR	Not Applicable
			Group DNot Classifiable as to			, , , , , , , , , , , , , , , , , , ,
Ethofumesate	26225-79-6	110601	Human Carcinogenicity	(2/24/94)	NR	Not Applicable
				,		Pheochromocytoma - adrenal glands (malignant); Sprague-
			Likely to be Carcinogenic to	OPP		Dawley rat rat (M); Cell carcinomas - thyroid gland; Sprague-
Ethoprop	13194-48-4	041101	Humans	(10/7/98)	Q1* = 2.81 E-2 (3/4)	Dawley & Fischer 344 rat (M);
Ethyl dipropylthiocarbamate			Not Likely to Be Carcinogenic	OPP		
(EPTC)	759-94-4	041401	to Humans	(8/31/99)	NR	Not Applicable
						Thyroid adenoma, carcinoma, & combined
						adenoma/carcinoma; F344 & CRCD rats (M & F). Thyroid
			Group BProbable Human	OPP		adenomas & carcinoma, pituitary & liver tumors; B6C3F1 &
Ethylene thiourea (ETU)	96-45-7	600016	Carcinogen	(3/19/90)	Q1* = 6.01 E-2 (3/4)	C57BL/6 x AKR mice (M & F).
			Multiple Descriptors: Not Likely			Combined thyroid follicular cell adenomas/carcinomas;
Etofenprox	80844-07-1	128965	Below a Defined Dose Range	(5/24/90)	NR	Sprague-Dawley rats (M & F).
			Not Likely to Be Carcinogenic	OPP		
Etoxazole	153233-91-1	107091	to Humans	(8/7/03)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Famoxadone	131807-57-3	113202	to Humans	(4/16/03)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Fenamidone	161326-34-7	046679	to Humans	(7/12/02)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Fenamiphos	22224-92-6	100601	carcinogenicity for Humans	(11/23/93)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Fenarimol	60168-88-9	206600	to Humans	(9/5/01)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Fenazaquin	120928-09-8	044501	To Humans	9/30/2008	NR	Not Applicable
						Thyroid follicular cell adenomas &/or combined
						adenomas/carcinomas; Sprague-Dawley rats (M).
			Group CPossible Human	OPP	0.44 0.75 7.45	Hepatocellular carcinomas (M); Hepatocellular adenomas &
Fenbuconazole	114369-43-6	129011	Carcinogen	(4/15/96)	Q1* = 3.59 E-3 (3/4)	combinded adenomas and/or carcinomas (F); CD-1 mice.
	40050 00 0	101001	Group EEvidence of Non-	OPP	NB	h
Fenbutatin-oxide	13356-08-6	104601	carcinogenicity for Humans	(10/8/92)	NR	Not Applicable
	100000 17 5		Not Likely to Be Carcinogenic	OPP	NB	h
Fenhexamide	126833-17-8	090209	to Humans	(3/4/99)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group EEvidence of Non-	OPP		
Fenitrothion	122-14-5	105901	carcinogenicity for Humans	(7/13/93)	NR	Not Applicable
Fenoxycarb	72490-01-8	125301	Likely to be Carcinogenic to Humans	OPP (12/22/97)	Q1* = 7.00 E-2 (3/4)	Lung adenomas, carcinomas & combined adenoma/carcinoma; Harderian gland adenomas; CD-1 mice (M).
Fenpropathrin	39515-41-8	127901	Not Likely to be Carcinogenic to Humans	OPP (12/22/03)	NR	Not Applicable
Fenpropidin	67306-00-7	012305	Suggestive Evidence Of Carcinogenic Potential	4/13/2009	NR	Pancreatic Islet Cells Sprague-Dawley Rat (M)
Fenpropimorph	67564-91-4	121402	Not Likely To Be Carcinogenic To Humans	10/19/2005	NR	Not Applicable
Fenpyroximate	134098-61-6	129131	Not Likely to Be Carcinogenic to Humans	OPP (2/19/97)	NR	Not Applicable
Fenthion	55-38-9	053301	Group EEvidence of Non- carcinogenicity for Humans	OPP (3/11/96)	NR	Not Applicable
Fenvalerate	51630-58-1	109301	Group EEvidence of Non-carcinogenicity for Humans	OPP (7/1/96)	NR	Not Applicable
Ferbam	128-04-1	034801	Likely to be Carcinogenic to Humans	OPP (4/6/00)	NR	C-cell thyroid tumors and hemangiomas; F344 & CD rats (M) Alveolar/bronchiolar adenomas & combined adenomas/carcinomas; B6C3F1 mice (F)
Fipronil	120068-37-3	129121	Group CPossible Human Carcinogen	OPP (7/18/95)	RfD Approach	Thyroid follicular cell adenomas, carcinomas & combined adenomas/ carcinomas (M); thyroid follicular cell adenomas and combined adenomas/carcinomas (F); Charles River CD rats.
Flazasulfuron	104040-78-0	119011	Not Likely To Be Carcinogenic To Humans	11/16/2005		Not Applicable
Flonicamid	158062-67-0	128016	Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential		NR	Nasolacrimal duct squamous cell carcinomas in female Wistar rats possibly treatment-related. Mitogenesis MOA accepted for lung tumors in CD-1 mive (M & F).
Florasulam	145701-23-1	129108	Not Likely To Be Carcinogenic To Humans	5/21/2009	NR	Not Applicable
Fluazifop-P-Butyl	79241-46-6	122809	Not Likely To Be Carcinogenic To Humans	9/19/2008	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE			QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
				DATE	METHOD	
			Suggestive Evidence of			
			Carcinogenicity, but Not			An increase in thyroid gland follicular cell tumors in male rats,
			Sufficient to Assess Human	OPP		and an increased incidence of hepatocellular tumors observed
Fluazinam	79622-59-6	129098	Carcinogenic Potential	(3/29/01)	NR	in the male mice was treatment-related
L			Not Likely To Be Carcinogenic			
Flubendiamide	272451-65-7	027602	To Humans	4/3/2008	NR	Not Applicable
L			Not Likely to Be Carcinogenic	OPP		
Flucarbazone-sodium	181274-17-9	114009	to Humans	(7/19/00)	NR	Not Applicable
			Group DNot Classifiable as to			
Fludioxonil	131341-86-1	071503	Human Carcinogenicity	(9/19/96)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Flufenacet (Thiaflumide)	142459-58-3	121903	to Humans	(7/16/97)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Flufenoxuron	101463-69-8	108203	To Humans	8/15/2006	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Flufenpyr-ethyl	188489-07-8	108853	to Humans	(6/8/03)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Flumetralin	62924-70-3	123001	To Humans	6/21/2007	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Flumetsulam (XRD-498)	98967-40-9	129016	carcinogenicity for Humans	(6/23/93)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Flumiclorac pentyl	87546-18-7	128724	carcinogenicity for Humans	(9/7/94)	NR	Not Applicable
	103361-09-7,		Not Likely to Be Carcinogenic	OPP		
Flumioxazin	141490-50-8	129034	to Humans	(2/22/01)	NR	Not Applicable
						Statistically significant increases in combined
			Group CPossible Human	OPP		adenomas/carcinomas of the lung (M); Malignant lymphocytic
Fluometuron	2164-17-2	035503	Carcinogen	(8/28/96)	Q1* = 1.80 E-2 (3/4)	lymphomas (F); CD-1 mice.
			Not Likely to Be Carcinogenic			
Fluopicolide	239110-15-7	027412	to Humans		RfD Approach	NA
			Likely To Be Carcinogenic To			Thyroid Follicular Cell C57BL/6J Mouse (M); Liver Wistar Rat
Fluopyram	658066-35-4	080302	Humans		Q1* = 1.55 E -2 (3/4)	(F)
			Not Likely To Be Carcinogenic			
Fluoxastrobin	361377-29-9	028869	To Humans	4/15/2010	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Fluridone	59756-60-4	112900	carcinogenicity for Humans	(7/1/85)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Not Likely To Be Carcinogenic			
Fluroxypyr	81406-37-3	128968	To Humans	10/3/2007	NR	Not Applicable
Fluroxypyr acid (see also PC			Not Likely to Be Carcinogenic	OPP		
Code 128968)	69377-81-7	128959	to Humans	(1/28/98)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Flurprimidol	56425-91-3	125701	To Humans	9/29/2005	NR	Not Applicable
			Likely to be Carcinogenic to	OPP		Pancreatic cell tumors (exocrine adenomas, islet cell adenomas, and combined islet cell tumors); Sprague-Dawley rats (M). Hepatocellular tumors (adenomas and combined
Fluthiacet methyl	117337-19-6	108803	Humans	(12/8/98)	Q1* = 2.07 E-1 (3/4)	adenoma/carcinoma); CD-1 mice (M & F). CD-1 mice (M & F).
			Group EEvidence of Non-	OPP		
Flutolanil	66332-96-5	128975	carcinogenicity for Humans	(6/9/94)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Flutriafol	76674-21-0	128940	To Humans	6/1/2009	NR	Not Applicable
			Group BProbable Human	OPP		Duodenum (carcinoma & adenoma); CD-1 & B6C3F1 mice (M
Folpet	133-07-3	081601	Carcinogen	(9/4/86)	Q1* = 1.86 E-3 (3/4)	& F); Hyperkeratosis/acanthosis; B6C3F1 mice (M).
Fomesafen	108731-70-0	123802	Not Likely to Be Carcinogenic to Humans	OPP (8/27/86)	NR	Peroxisome proliferator-activated receptor alpha (PPARa) as the mode of action for fomesafen-induced liver tumors in mice.
			Group EEvidence of Non-	OPP		
Fonofos	944-22-9	041701	carcinogenicity for Humans	(11/10/93)	NR	Not Applicable
Forchlorfenuron	68157-60-8	128819	Not Likely To Be Carcinogenic To Humans	3/11/2008	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Formasulfuron	173159-57-4	122020	to Humans	(9/19/01)	NR	Not Applicable
Formetanate hydrochloride	23422-53-9	097301	Group EEvidence of Non- carcinogenicity for Humans	OPP (5/20/96)	NR	Not Applicable
Fosetyl-Al	39148-24-8	123301	Not Likely	OPP (4/22/99)	NR	Not Applicable
Fosthiazate	98886-44-3	129022	Not Likely to Be Carcinogenic to Humans	OPP (9/15/03)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
				IDAIL	INICITIOD	Multiple tumors were seen at multiple sites in two species
						including both benign & malignant liver tumors in Sprague-
						Dawley rats (M&F) and CD-1 mice, rare tumors such as
			Likely to be Carcinogenic to	OPP		stomach & testicular tumors in rats (M) & lung tumors in mice
Furiazole (MON 13900)	121776-33-8	911596	Humans	(9/21/99)	Q1* = 2.74 E-2 (3/4)	(M & F).
			Group BProbable Human	OPP		Liver tumors (M & F); Urothelial tumors (M); Sprague-Dawley
Furmecyclox	60568-05-0	122601	Carcinogen	(7/3/85)	Q1* = 2.98 E-2 (2/3)	rats
			Not Likely to Be Carcinogenic	OPP		
Gamma Cyhalothrin	76703-62-3	128807	to Humans	(3/01/04)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Glufosinate-ammonium	77182-82-2	128850	to Humans	(5/17/99)	NR	Not Applicable
			Not Likely to Be Carcinogenic			
Glutaraldehyde	111-30-8	043901	to Humans		NR	Not applicable
			Group EEvidence of Non-	OPP		
Glyphosate	1071-83-6	417300	carcinogenicity for Humans	(12/16/91)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Halosulfuron methyl (MON 1200)	100784-20-1	128721	to Humans	(2/26/98)	NR	Not Applicable
			Group BProbable Human	OPP		Liver tumors [adenomas (M), carcinomas (F) &
Haloxyfop-methyl	690806-40-2	125201	Carcinogen	(9/18/89)	Q1* = 7.39 E+0 (2/3)	adenomas/carcinomas (M & F)]; B6C3F1 mice.
			Group CPossible Human	OPP		
Hexaconazole	79983-71-4	128925	Carcinogen	(1/21/99)	Q1* = 1.6 E-2 (3/4)	Benign Leydig cell tumors; Wistar (Alpk:APfSD) rat (M)
			Group DNot Classifiable as to			
Hexazinone	51235-04-2	107201	Human Carcinogenicity	(7/27/94)	NR	Not Applicable
						Liver (hepatocellular carcinomas & carcinomas/adenomas
			Likely To Be Carcinogenic To	OPP		combined) in B6C3F1 mice (F; Mammary Gland
Hexythiazox	78587-05-0	128849	Humans	(3/16/88)	RfD Approach	(fibroadenomas) Fischer 344 Rat (M)
			Not Likely to Be Carcinogenic	OPP		
HOE107892	135590-91-9	811800	to Humans	(10/13/98)	NR	Not Applicable
l			Group CPossible Human	OPP		Lung adenomas & combined adenomas/carcinomas; CD-1
Hydramethylnon	67485-29-4	118401	Carcinogen	(3/28/91)	RfD Approach	mice (F).
						0 1 1 1 1 1 0 1 1 (0 5) 5 5 1 (5)
				000		Ovarian granulosa-theca tumors; CRL:CD-1 (ICR)BR mice (F)
	100 04 0	04.4000	Group CPossible Human	OPP	04* 004 5 0 (0/1)	[Hydrogen cyanamide]. Positive trend in hemangiosarcomas;
Hydrogen cyanamide	420-04-2	014002	Carcinogen	(9/15/93)	Q1* = 6.64 E-2 (3/4)	B6C3F1 mice (M) [Calcium cyanamide].
	44000 40.0	400000	Group DNot Classifiable as to		ND	Not A collected
Hydroprene	41096-46-2	486300	Human Carcinogenicity	(6/8/95)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
	05554.44.0	144004	Likely to be Carcinogenic to	OPP	04+ 044 5 0 (0/4)	An increase (both trend and pair-wise) in combined liver adenomas/ carcinomas in male Swiss albino mice and male Wistar rats and an increase in combined thyroid follicular
Imazalil	35554-44-0	111901	Humans	(12/7/99)	Q1* = 6.11 E-2 (3/4)	adenomas/carcinomas in male Wistar rats.
Imazamethabenz	81405-85-8	128842	Group DNot Classifiable as to Human Carcinogenicity	(6/11/87)	NR	Not Applicable
Imazamox	114311-32-9	129171	Not Likely to Be Carcinogenic to Humans	OPP (2/27/97)	NR	Not Applicable
Imazapic	81334-60-3	129041	Group EEvidence of Non-carcinogenicity for Humans	OPP (9/27/95)	NR	Not Applicable
Imazapyr	81334-34-1	128821	Group EEvidence of Non-carcinogenicity for Humans	OPP (10/5/95)	NR	Not Applicable
Imazaquin Acid	81335-37-7	128848	Not Likely To Be Carcinogenic To Humans	10/31/2005	NR	Not Applicable
Imazethapyr	81335-77-5	128922	Not Likely to Be Carcinogenic to Humans	OPP (1/31/02)	NR	Not Applicable
Imazosulfuron	122548-33-8	118602	Not Likely To Be Carcinogenic To Humans	3/13/2009	NR	Not Applicable
Imidacloprid	105827-78-9	129099	Group EEvidence of Non-carcinogenicity for Humans	OPP (11/10/93)	NR	Not Applicable
Indaziflam	950782-86-2	080818	Not Likely To Be Carcinogenic To Humans	4/22/2010	NR	Not Applicable
Indoxacarb	173584-44-6	067710	Not Likely to Be Carcinogenic to Humans	OPP (7/17/00)	NR	Not Applicable
			Multiple Descriptors: Not Likely to be Carcinogenic to Humans at doses that do not alter rat			
Iodomethane	74-88-4	000011	thyroid hormone homeostasis		RfD	Thyroid follicular cell tumors in male rats and mice
lodosulfuran	144550-36-7	122021	Not Likely to Be Carcinogenic to Humans	OPP (1/5/04)	NR	Not Applicable
Ipoconazole	125225-28-7	125618	Not Likely To Be Carcinogenic To Humans	5/28/2008	NR	Not Applicable
Iprodione	36734-19-7	109801	Likely to be Carcinogenic to Humans	OPP (11/19/97)	Q1* = 4.39 E-2 (3/4)	Hepatocellular tumors (M&F); Ovarian luteomas (F); CD-1 mice. Testicular interstitial cell tumors (Leydig cell); Crl:CD(SD)BR rats (M).

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
						Osteosarcomas, (M) transitional cell papillomas of the urinary
						bladder (F), mixed Mullerian tumors of the uterus,(F) and
			Likely to be Carcinogenic to	OPP		follicular cell adenomas/carcinomas of the thyroid gland (F) in
Iprovalicarb	140923-17-7	098359	Humans	(2/6/02)	Q1* = 4.47E-4 (3/4)	Wistar (Hsd/WIN:WU) rats
			Group EEvidence of Non-	OPP		
Isofenphos	25311-71-1	109401	carcinogenicity for Humans	(1/13/98)	NR	Not Applicable
			Group CPossible Human	OPP		
Isophorone	78-59-1	047401	Carcinogen	(9/2/99)	Q1* = 6.08 E-4 (3/4)	Preputial gland carcinomas; F344/N rats (M)
			Group CPossible Human	OPP		
Isoxaben	82558-50-7	125851	Carcinogen	(1/4/89)	NR	Hepatocellular adenomas; B6C3F1 mice (M & F).
			Not Likely to Be Carcinogenic	OPP		
Isoxadifen-ethyl	163520-33-0	823000	to Humans	(1/29/01)	NR	Not Applicable
						Statistically significant increases in liver tumors in both sexes
			Likely to be Carcinogenic to	OPP		of mice & rats; statistically significant increases in thyroid
Isoxaflutole	141112-29-0	123000	Humans	(8/6/97)	Q1* = 1.02 E-2 (3/4)	tumors in male rats.
			Not Likely To Be Carcinogenic			
Kasugamycin	6980-18-3	230001	To Humans	4/29/2009	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
Kathon 886	55965-84-9	107106	Human Carcinogenicity	(6/30/95)	MOE Approach	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
KBR 3023	119515-38-7	070705	to Humans	(6/9/99)	NR	Not Applicable
						Liver tumors (hepatocellular adenomas, hepatocellular
			Likely to be Carcinogenic to	OPP		carcinomas & combined adenomas/carcinomas); Wistar rats
Kresoxim-methyl	143390-89-0	129111	Humans	(8/19/99)	Q1* = 2.90 E-3 (3/4)	(M & F).
				,	,	
			Multiple Descriptors: Likely to			
			be Carcinogenic in Humans at			
			High Doses. Not Likely to be			Hepatocellular carcinomas (M); Hepatocellular adenomas &
			Carcinogenic to Humans at	OPP		carcinomas (M & F); CD-1 mice. Liver neoplastic nodules;
Lactofen	77501-63-4	128888	Low Doses	(4/8/02)	MOE approach	Sprague-Dawley rats (M & F).
		1		,		, , , , , , , , , , , , , , , , , , , ,
			Group DNot classifiable as to	OPP		
Lambda cyhalothrin	91465-08-6	128897	Human Carcinogenicity	(9/12/02)	NR	Not Applicable
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		
Lindane	58-89-9	009001	Carcinogenic Potential	(11/29/01)	NR	Lung tumors (benign) in female mice only

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT	QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group CPossible Human	OPP	METHOD	Testigular tumora, CD rate (M), Handtocallular adapament CD
Linuron	330-55-2	035506	Carcinogen		NR	Testicular tumors; CD rats (M); Hepatocellular adenomas; CD-1 mice (M & F).
Lilidioii	330-33-2	033300	Suggestive Evidence of	(11/20/01)	INIX	Occurrence of liver tumors in male & female B6C3F1 mice & in
			Carcinogenicity, but Not			female Fischer 344 rats only at excessive doses. Presence of
			Sufficient to Assess Human	OPP		a few rare tumors, oral palate mucosa in F & nasal respiratory
Malathion	121-75-5	057701	Carcinogenic Potential	(4/28/00)	NR	epithelium in M&F Fischer 344 rats.
Ivialatilion	121-73-3	037701	Group EEvidence of Non-	OPP	INIX	epithelium in war i ischer 344 rats.
Maleic hydrazide	123-33-1	051501	carcinogenicity for Humans	(11/10/93)	NR	Not Applicable
Maleic Hydrazide	123-33-1	051501	carcinogenicity for numaris	(11/10/93)	INIX	Not Applicable
						Thyroid follicular cell adenomas & carcinomas, combined
			Group BProbable Human	OPP	Q1* = 6.01 E-2 (3/4)	thyroid follicular cell adenomas and/or carcinomas; Crl:CD(BR)
Mancozeb	8018-01-7	014504	Carcinogen	(7/7/99)	Based on ETU	rats (M & F).
	00.00.	000.	Not Likely To Be Carcinogenic	(.,,,,,,,	20000 011 2 1 0	indic (in dir)
Mandipropamid	374726-62-2	036602	To Humans	4/27/2010	NR	Not Applicable
manaipropaima	020 02 2	000002	Group BProbable Human	OPP	Q1* = 6.01 E-2 (3/4)	Hepatocellular adenomas in M & F mice, no acceptable study
Maneb	12427-38-2	014505	Carcinogen	(7/7/99)	Based on ETU	in rats
MB46513 (photodegradate of		0000	Not Likely to Be Carcinogenic	OPP	20000 011 2 1 0	III Tato
Fipronil)	120067-83-6	600050	to Humans	(12/6/00)	NR	Not Applicable
	.2000. 00 0	00000	Not Likely to Be Carcinogenic	OPP		The state of the s
MCPA + Salts	94-74-6	030501	to Humans	(10/29/03)	NR	Not Applicable
			Not Likely To Be Carcinogenic	(10,00)		, , , , , , , , , , , , , , , , , , ,
MCPB Acid	94-81-5	019201	To Humans	10/1/2008	NR	Not Applicable
			Suggestive Evidence of		1	, , , , , , , , , , , , , , , , , , ,
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		Hepatocellular adenomas and carcinomas in female
Mecoprop-P	16484-77-8	129046	Carcinogenic Potential	(1/15/03)	NR	B6C3F1/CrIBR mice.
				,		
			Not Likely to Be Carcinogenic	OPP		
Mefenoxam	70630-17-0	113502	to Humans	(5/17/00)	NR	Not Applicable
			Not Likely To Be Carcinogenic		l	
Mefluidide	53780-34-0	114001	To Humans	4/2/2007	NR	Not Applicable
			Group DNot Classifiable as to			
Melamine	108-78-1	777201	Human Carcinogenicity	(7/29/92)	NR	Not Applicable
l.,			Likely to be Carcinogenic to			Benign and malignant liver tumors in Female Fisher 344 rats
Mepanipyrim	110235-97-7	288203	Humans		Q1* = 1.35 E-2 (3/4)	and both sexes of B6C3F1 mice
			l	OPP		
Mepiquat Chloride	24307-26-4	109101	Not Likely	(2/19/03)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
Meptyldinocap (DE-126/Dinocap			Group EEvidence Of Non-			
II)	131-72-6	036000	Carcinogenicity For Humans	3/17/2009	NR	Not applicable
						Adrenal gland tumors (M & F), some evidence of preputial
			Group CPossible Human	OPP		gland tumors (M) & equivocal evidence for pituitary gland
Mercaptobenzothiazole, 2-	149-30-4	051701	Carcinogen	(11/19/92)	RfD Approach	tumors (M); F344/N rats.
			Not Likely to Be Carcinogenic	OPP		
Mesosulfuron methyl	208465-21-8	122009	to Humans	(3/4/04)	NR	Not Applicable
·			Not Likely to Be Carcinogenic	OPP		
Mesotrione	104206-82-8	122990	to Humans	(4/12/01)	NR	Not Applicable
			Not Likely To Be Carcinogenic	,		
Metaflumizone	139968-49-3	281250	To Humans	1/26/2010	NR	Not Applicable
			Group EEvidence of Non-	OPP		· ·
Metalaxyl	57837-19-1	113501	carcinogenicity for Humans	(12/31/85)	NR	Not Applicable
,			Suggestive Evidence of	, , , , ,		
Metaldehyde	108-62-3	053001	Carcinogenic Potential		NR	Benign liver tumors in female rats and both sexes of mice
		100000	Likely To Be Carcinogenic To	OPP		Malignant angiosarcomas (by both pair-wise & trend analysis)
Metam sodium	137-42-8	039003	Humans	(3/21/00)	Q1* = 1.98 E-1(3/4)	CD-1 Mouse (M & F)
motani osaisin	.0 0	00000	Not Likely to Be Carcinogenic	(6/2 // 66)	Q: 1100 = 1(0/1.)	(III & I)
Metconazole	125116-23-6	125619	to Humans		NR	Mitogenesis MOA for liver tumors in both sexes of CD-1 mice
Motochazoro	120110 20 0	120010	Not Likely to Be Carcinogenic	OPP	1111	Integration montral interstantion in both coxec of ob 1 miles
Methamidophos	10265-92-6	101201	to Humans	(2/12/98)	NR	Not Applicable
Modification	10200 02 0	101201	Group CPossible Human	OPP	1111	Trock reprised to
Methidathion	950-37-8	100301	Carcinogen	(2/19/88)	NR	Liver tumors (benign and malignant); CD-1 mice (M).
THOU HAGUIIOTI	000 07 0	100001	Group DNot Classifiable as to		1111	Error tumoro (comigni and manghanty, eb i mico (m).
Methiocarb	2032-65-7	100501	Human Carcinogenicity	(3/2/93)	RfD Approach	Not Applicable
Wethoods	2002 00 7	100001	Group EEvidence of Non-	OPP	Trib / ipprodon	Not Applicable
Methomyl	16752-77-5	090301	carcinogenicity for Humans	(10/26/96)	NR	Not Applicable
Wethorny	10/32 // 3	030301	Not Likely to Be Carcinogenic	OPP	IVIX	Τνοι Αρριισασίο
Methoxyfenozide	161050-58-4	121027	to Humans	(7/1/99)	NR	Not Applicable
Wellioxyleriozide	101030-30-4	121021	to i idilialis	OPP	IVIX	Not Applicable
Methyl bromide	74-83-9	053201	Not Likely	(8/4/92)	NR	Not Applicable
wetryr bronnide	74-03-9	033201	Not Likely	(6/4/92)	INIX	Based on Metam Sodium data: Malignant angiosarcomas (by
						both pair-wise & trend analysis); C57BL/10JfCD-1/Alpk mice
			Group P. Probable Human	OPP		
Mathyliaathiaayanata	6217 10 6	069103	Group BProbable Human		O1* 1.00 E 1.(3/4)	(M & F). Malignant hemangiosarcomas; Hsd/Ola: Wistar rats
Methyl isothiocyanate	6317-18-6	068103	Carcinogen	(2/2200)	Q1* = 1.98 E-1 (3/4)	(M).
Mathyl parathias	200.00.0	050504	Not Likely to Be Carcinogenic	OPP	ND	Not Applicable
Methyl parathion	298-00-0	053501	to Humans	(12/1/97)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
				DATE	INIT I HOD	Thyroid follicular cell adenomas & carcinomas, combined
			Group BProbable Human	OPP	Q1* = 6.01 E-2 (3/4)	thyroid follicular cell adenomas and/or carcinomas; Crl:CD(BR)
Metiram	9006-42-2	014601	Carcinogen	(7/7/99)	Based on ETU	rats (M & F).
THOUGHT.	0000 12 2	011001	Likely to be Carcinogenic to	(171700)	Dadou on E i o	Tato (m a r).
Metofluthrin	240444-70-6	109709	Humans		Q1* = 1.62 E -2 (3/4)	Liver tumors in M&F Wistar rats.
			Group CPossible Human	(OPP		Liver adenomas and combined adenomas/carcinomas;
Metolachlor	51218-45-2	108801	Carcinogen	(11/16/94)	MOE Approach	Charles River CD (SD)BR rats (F).
			Suggestive Evidence of	(* *, * *, * *,		(*)
Metrafenone	220899-03-6	000325	Carcinogenic Potential		NR	Benign Liver Tumors in Male CD-1 Mice
			Group DNot Classifiable as to	OPP		
Metribuzin	21087-64-9	101101	Human Carcinogenicity	(5/16/95)	NR	Not Applicable
				,		
			Not Likely to Be Carcinogenic	OPP		
Metsulfuron methyl	74223-64-6	122010	to Humans	(3/14/02)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Mevinphos	7786-34-7	015801	To Humans	5/17/2000	NR	Not Applicable
						Statistically significant increases in hepatocellular adenomas;
			Group CPossible Human	OPP		CD-1 mice (M & F). Statistically significant increases for
MGK 264	113-48-4	057001	Carcinogen	(6/7/95)	RfD Approach	thyroid follicular cell adenomas; Crl:CDBR rats (M).
						Multiple malignant & benign tumors [liver (M & F), kidney (M &
						F), testes (M) & uterine (F); CD rats. Multiple malignant
			Group BProbable Human	OPP		tumors [liver (M & F) & lung/bronchiolar tumors (M)]; CD-1
MGK Replellent 326	136-45-8	047201	Carcinogen	(11/12/02)	Q1* = 1.6 E-3 (3/4)	mice.
			Suggestive Evidence of			Statistically significant increase in combined adenomas &
			Carcinogenicity, but Not			carcinomas in the kidney; CrI:CD(SD)BR rat (M). There was
L			Sufficient to Assess Human	OPP		equivocal evidence that Molinate induced an increase in
Molinate	2212-67-1	041402	Carcinogenic Potential	(12/14/00)	NR	testicular tumors.
						Hanatacallular adanamas, carainamas 9 cambinad
						Hepatocellular adenomas, carcinomas & combined adenomas/carcinomas; (M&F) rats & mice. Stomach
						squamous cell papillomas & combined papillomas/carcinomas;
						M rats & M&F mice. Bile duct cholangiomas/carcinomas; M
			Likely to be Carcinogenic to	OPP		rats. Bronchio alveolar adenomas, combined adenomas/
MON 4660	71526-07-3	600046	Humans	(12/9/99)	Q1* = 4.85 E-2 (3/4)	carcinomas; M mice. Sprague Dawley rats, CD 1 mice.
Monosodium acid	7 1320-07-3	000040	Not Likely to Be Carcinogenic	OPP	Q1 - 7.00 L-2 (0/4)	carolinomas, in filice. Oprague Dawiey rats, OD 1 filice.
methanearsonate (MMA)	2163-80-6	013803	to Humans	(7/26/00)	NR	Not Applicable
memanearsonate (wiwiA)	2103-00-0	013003	to i iuiiialis	(1/20/00)	LALZ	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT	QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
				DATE	METHOD	
MONAA salai sasali	5000 05 4	040000	Not Likely to Be Carcinogenic	OPP	ND	No. C. A. S. Paral II.
MSMA-calcium salt	5902-95-4	013806	to Humans	(12/14/00)	NR	Not Applicable
	20074 20 2	400057	Group EEvidence of Non-	OPP	NID.	
Myclobutanil	88671-89-0	128857	carcinogenicity for Humans	(6/16/94)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Naled	300-76-5	034401	carcinogenicity for Humans	(8/31/94)	NR	Not Applicable
l.,			Not Likely To Be Carcinogenic			
Napropamide	15299-99-7	103001	To Humans	7/7/2005	NR	Not Applicable
			Group DNot Classifiable as to			
Naptalam Sodium Salt	132-67-2	030703	Human Carcinogenicity	(9/7/94)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Napthalene Acetates	2122-70-5	056008	To Humans	3/5/2009	NR	Not applicable.
			Group EEvidence of Non-	OPP		
Nicosulfuron	111991-09-4	129008	carcinogenicity for Humans	(9/1/98)	NR	Not Applicable
			Likely to be Carcinogenic to	OPP		Increase in liver tumors in B6C3F M & F mice; epididymal
Nitrapyrin	1929-82-4	069203	Humans	(5/5/00)	Q1* = 4.25 E-2 (3/4)	sarcomas in M mice
						Statistically significant increase in comparison to controls in
						liver adenomas & combined liver adenomas & carcinomas, as
						well as the statistically significant positive trend for these
			Group CPossible Human	OPP		hepatocellular adenomas & combined adenomas &
Norflurazon	27314-13-2	105801	Carcinogen	(11/2/90)	NR	carcinomas; CD-1 mice (M
			Not Likely to Be Carcinogenic	OPP		
Not Applicable	77-48-5	006317	to Humans	(8/28/00)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Novaluron	116714-46-6	124002	to Humans	(2/4/04)	NR	Not Applicable
Orthophenylphenol (see also PC			Not Likely to Be Carcinogenic	OPP		
064104)	90-43-7	064103	to Humans	(8/24/94)	NR	Not Applicable
Orthophenylphenol, Sodium salt			Not Likely to Be Carcinogenic	OPP		
(see also PC 064103)	132-27-4	064104	to Humans	(8/24/94)	NR	Not Applicable
			Suggestive Evidence of			
Orthosulfamuron	213464-77-3	108209	Carcinogenic Potential		RfD Approach	Thyroid follicular cell tumors in male Han Wistar rats.
			Likely to be Carcinogenic to	OPP		
Oryzalin	19044-88-3	104201	Humans	(5/14/03)	Q1* = 7.79 E-3 (3/4)	Multiple sites (thyroid, mammary); F344 rats (M & F).
			Group CPossible Human	OPP		Liver tumors (malignant, combined malignant & benign); CD
Oxadiazon	19666-30-9	109001	Carcinogen	(5/1/01)	Q1* = 7.11 E-2 (3/4)	CD-1 mice (M & F), Wistar rats (M)

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group CPossible Human	OPP		Hepatocellular adenomas (by pair-wise comparison & with a
Oxadixyl	77732-09-3	126701	Carcinogen	(1/4/89)	Q1* = 5.3 E-2 (2/3)	dose- related trend); Han-Wistar rats (M & F).
			Group EEvidence of Non-	OPP		
Oxamyl	23135-22-0	103801	carcinogenicity for Humans	(11/5/96)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Oxydemeton-methyl	301-12-2	058702	to Humans	(7/24/97)	NR	Not Applicable
			Likely To Be Carcinogenic To	OPP		Liver (adenomas, carcinomas & combined adenomas and/or
Oxyfluorfen	42874-03-3	111601	Humans	(9/29/89)	Q1* = 7.32 E-2 (3/4)	carcinomas); CD-1 mice (M).
			Group DNot Classifiable as to	OPP	` ,	
Oxytetracycline	2058-46-0	006308	Human Carcinogenicity	(12/18/92)	NR	Not Applicable
Oxythioquinox	2439-01-2	054101	Group BProbable Human Carcinogen	OPP (2/15/96)	Q1* = 3.42 E-2 (3/4)	Lung tumors; NMRI mice (M). Hepatocellular tumors (M & F) and rare kidney tumors (F); F344 rats. Data showing chemical has clastogenic activity provided additional support.
Paclobutrazol	76738-62-0	125601	Group DNot Classifiable as to	OPP (6/23/94)	NR	Not A - Post I
Paradichlorobenzene	106-46-7	061501	Human Carcinogenicity Multiple Descriptors: Not likely at doses that don't perturb homeostasis of liver cell proliferation.	OPP (4/27/89)	NR	Not Applicable Liver (adenomas and carcinomas); B6C3F1 mice (M & F); Mitogenic MOA established
Paranitrophenol	100-02-7	056301	Group DNot Classifiable as to Human Carcinogenicity	OPP (5/14/96)	NR	Not Applicable
Paraquat dichloride	1910-42-5	061601	Group EEvidence of Non- carcinogenicity for Humans	OPP (3/15/89)	NR	Not Applicable
Parathion, ethyl-	56-38-2	057501	Group CPossible Human Carcinogen	OPP (9/11/91)	RfD Approach	Adrenal cortical tumors (adenomas + carcinomas; Thyroid follicular cell adenomas & pancreatic cell carcinomas; Osborne-Mendel rat (M) Benign pancreatic tumors; Wistar rat (M)
			Not Likely to Be Carcinogenic	OPP		
Pebulate	1114-71-2	041403	to Humans	(12/7/98)	NR	Not Applicable
			Group CPossible Human	OPP		
Pendimethalin	40487-42-1	108501	Carcinogen	(7/24/92)	RfD Approach	Thyroid follicular cell adenomas; Sprague-Dawley rats (M & F).

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Suggestive Evidence of	IDAIL	INICITIOD	
			Carcinogenicity, but Not			
			Sufficient to Assess Human			
Penoxulam	219714-96-2	119031	Carcinogenic Potential		NR	Mononuclear Cell Leukemia (MNCL) in Fisher 344 Male Rats
			Group CPossible Human	OPP		Thyroid follicular cell adenomas (by both pair-wise and trend
Pentachloronitrobenzene (PCNB)	82-68-8	056502	Carcinogen	(12/18/92)	RfD Approach	analysis) in males with a positive trend in females; CD rats.
(0)				(12,10,0)	, , , , 	Hepatocellular adenomas & carcinomas, adrenal medulla
						pheochromocytomas & malignant pheochromocytomas, &/or
			Group BProbable Human	OPP		hemangiosarcomas & hemangiomas in one or both sexes of
Pentachlorophenol	87-86-5	063001	Carcinogen	(1/3/91)	Not Determined	B6C3F1 mice.
·			Likely to be Carcinogenic to	OPP		Lung (benign) tumors in female and liver tumors in both sexes
Permethrin	52645-53-1	109701	Humans	(10/23/02)	Q1* = 9.567 E-3 (3/4)	of CD-1 mice.
			Group DNot Classifiable as to	OPP		
Phenmedipham	13684-63-4	098701	Human Carcinogenicity	(4/28/93)	NR	Not Applicable
			Suggestive Evidence of			Vascular tumors in female Wistar rats, male & female
			Carcinogenicity, but Not			C5B1/10JfCD-1/Alpk mice following oral exposure; vascular
			Sufficient to Assess Human	OPP		tumors in female Alderley Park mice following dermal
PHMB	32289-58-0	111801	Carcinogenic Potential	(4/9/03)	NR	exposure.
			Group EEvidence of Non-	OPP		
Phorate	298-02-2	057201	carcinogenicity for Humans	(12/30/93)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Phosalone	2310-17-0	097701	to Humans	(8/12/99)	NR	Not Applicable
						Increase (both trend & pair-wise) in combined liver
			Suggestive Evidence of			adenomas/carcin- omas in male B6C3F1 mice but only trends
			Carcinogenicity, but Not			for increase of liver adenomas/carcinomas & mammary
			Sufficient to Assess Human	OPP		adenocarcinomas in female B6C3F1 mice. There was no
Phosmet	732-11-6	059201	Carcinogenic Potential	(10/27/99)	NR	evidence of carcinogenicity in an acceptable rat study.
			Group CPossible Human	OPP		Bladder transitional cell carcinoma; Hepatocellular carcinoma;
Phosphamidon	13171-21-6	018201	Carcinogen	(5/31/89)	NR	Sprague-Dawley rats (M).
			Group EEvidence of Non-	OPP		
Phostebupirim	96182-53-5	129086	carcinogenicity for Humans	(4/27/97)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Picloram Acid	1918-02-1	005101	carcinogenicity for Humans	(2/10/89)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT	QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
		ı	O. F. F. H. L. L. (No.	DATE	METHOD	
Dielerens Asid Ethydhoud Feter	2545 60 0	005400	Group EEvidence of Non-	OPP	ND	Net Applicable
Picloram Acid Ethylhexyl Ester	2545-60-0	005103	carcinogenicity for Humans	(2/10/89) OPP	NR	Not Applicable
Picloram Acid Potassium Salt	35832-11-2	005104	Group EEvidence of Non-carcinogenicity for Humans		NR	Not Applicable
Picloram Acid	33032-11-2	005104	Group EEvidence of Non-	(2/10/89) OPP	INIX	Not Applicable
Triisopropanolamine Salt	6753-47-5	005102	carcinogenicity for Humans	(2/10/89)	NR	Not Applicable
Thisopropanoiamine Sait	0/03-4/-0	005102	Data Are Inadequate for an	(2/10/69)	INIX	Not Applicable
			Assessment of Human			
Dinavadan	202072 20 0	1.47500			NR	Net Applicable
Pinoxaden	293973-20-8	147500	Carcinogenic Potential		INK	Not Applicable
			Crave C. Bassible Human	ODD	DfD and MOE	Increased incidence of hepatocellular tumors (M & F)
Dia anamal bastonida	E4 00 0	007504	Group CPossible Human	OPP	RfD and MOE	(adenomas, carcinomas, combined adenomas/carcinomas in
Piperonyl butoxide	51-03-6	067501	Carcinogen	(6/7/95)	Approaches	M and adenomas in F; CD-1 mice
			Libebote he Consideration to			Multiple benign and/or malignant tumors (liver, lung, ovary,
B	00400 00 0	100101	Likely to be Carcinogenic to		0.44 0.500 5 0.40(4)	mammary gland) seen in male and female Swiss mice and
Pirimicarb	23103-98-2	106101	Humans	000	Q1* = 3.526 E -2 (3/4)	lung tumors in female CD-1 mice
B	22222 22 7	100100		OPP	ND	N A II I .
Pirimiphos-methyl	29232-93-7	108102	Cannot Be Determined	(1/29/98)	NR	Not Applicable
Del continue de Detector		100070	Inadequate Information to		ND	Nich Acceptable
Polymeric Betaine		103679	Assess Carcinogenic Potential	000	NR	Not Applicable
	7770 50 0	00000	Not Likely to Be Carcinogenic	OPP	ND	N A II I .
Potassium dichromate	7778-50-9	068302	to Humans	(8/28/01)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP	l	
Prallethrin	23031-36-9	128722	to Humans	(6/27/03)	NR	Not Applicable
			Group DNot Classifiable as to			
Primisulfuron-methyl	86209-51-0	128973	Human Carcinogenicity	(5/3/90)	NR	Not Applicable
			Group CPossible Human	OPP		Hepatocellular adenoma & carcinoma, combined
Prochloraz	67747-09-5	128851	Carcinogen	(7/1/88)	Q1* = 1.5 E-1 (2/3)	adenoma/carcinoma; CD-1 (M & F).
						Interestitial call adaptoma (M): Distriture adaptoma (E): Oaharna
						Interstitial cell adenoma (M); Pituitary adenoma (F); Osborne- Mendel rats. Liver adenomas & combined
			Crown D. Drobelle House	ODD		adenomas/carcinomas; B6C3F1 mice (F). Additionally, a rare
Dra ay maida na a	22000 40 0	100044	Group BProbable Human	OPP	O4* 4 220 F 0 (0/4)	variant of hepatocellular carcinoma, hepatoblastoma, had a
Procymidone	32809-16-8	129044	Carcinogen	(4/5/91)	Q1* = 1.339 E-2 (3/4)	significant increasing trend in M B 6C3F1 mice.
			On the Breeding Head	000		Thyroid follicular cell neoplasia; Pancreatic adenomas;
	00004 5: 5	44000	Group CPossible Human	OPP		Sprague- Dawley rats (M & F). Fibrosarcomas; CD-1 mice
Prodiamine	29091-21-2	110201	Carcinogen	(7/15/91)	RfD Approach	(M).

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group EEvidence of Non-	OPP		
Profenofos	41198-08-7	111401	carcinogenicity for Humans	(2/6/95)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Prohexadione	127277-53-6	112600	to Humans	(4/14/00)	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
Prometon	1610-18-0	080804	Human Carcinogenicity	(9/17/92)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Prometryn	7287-19-6	080805	carcinogenicity for Humans	(7/25/94)	NR	Not Applicable
			Group BProbable Human	OPP		Benign testicular interstitial cell tumors (M); Uncommon thyroid follicular cell adenomas (M&F); Crl:CD(SD)BR rats.
Pronamide	23950-58-5	101701	Carcinogen	(5/26/93)	Q1* = 2.59 E-2 (3/4)	Hepatocellular carcinomas; B6C3F1 mice (M).
Propachlor	1918-16-7	019101	Likely to be Carcinogenic to Humans	OPP (10/16/97)	Q1* = 3.2 E-2 (3/4)	Multiple tumors/multiple sites; Rare stomach tumor; Fischer 344 rat (M); Thyroid tumors & granulosa/theca cell tumors; Sprague-Dawley rats (M & F). Hepatocellular tumors; CD-1 mice (M).
, repairie.	10.0.0.	0.0.0.		OPP	Q: 0:2 2 2 (0; 1)	
Propamocarb hydrochloride	25606-41-1	119302	Not Likely	(5/31/00)	NR	Not Applicable
Propanil	709-98-8	028201	Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential	OPP (6/19/01)	NR	Testicular interstitial cell adenomas in male rats. Hepatocellular adenomas in female rats at an excessively toxic doses
			Group BProbable Human	OPP		Statistically significant increases in undifferentiated sarcomas
Propargite	2312-35-8	097601	Carcinogen	(7/23/92)	Q1* = 1.92 E-1 (3/4)	in the jejunum; Crl:CDBR rat (M & F).
Propazine	139-40-2	080808	Not Likely to Be Carcinogenic to Humans	OPP (5/8/97)	NR	Mammary tumors in female rats (SD)
			Not Likely to Be Carcinogenic	OPP		
Propetamphos	31218-83-4	113601	to Humans	(12/2/98)	NR	Not Applicable
Propiconazole	60207-90-1	122101	Group CPossible Human Carcinogen	OPP (9/14/92)	RfD Approach	Hepatocelluar adenomas, carcinomas, & adenomas/carcinomas combined; CD-1 mice (M).
Propoxur	114-26-1	047802	Group BProbable Human Carcinogen	OPP (6/17/96)	Q1* = 3.69 E-3 (3/4)	Bladder carcinomas (rare), papillomas & combined combined carcinoma/ papilloma (M&F); Wistar rats. Statistically significant increases in hepatocellar adenomas & adenomas & combined adenoma/carcinoma; B6C3F1 mice (M).
			Not Likely to Be Carcinogenic			
Propoxycarbazone-Sodium	181274-15-7	122019	to Humans		NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Data Are Inadequate for an			
			Assessment of Human	OPP		
Prosulfuron	94125-34-5	129031	Carcinogenic Potential	(1/24/00)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Prothioconazole	178928-70-6	113961	To Humans	3/5/2010	NR	Not Applicable
						Liver tumors- Hepatomas and combined adenomas and/or
						carcinomas; Tif:RAIf(SPF) Sprague-Dawley rats (F). Liver
			Likely to be Carcinogenic to	OPP		carcinomas and combined hepatomas and/or carcinomas;
Pymetrozine	123312-89-0	101103	Humans	(8/24/99)	Q1* = 1.19 E-2 (3/4)	Tif:MAGf(SPF) mice (M & F).
			Not Likely to Be Carcinogenic	OPP		
Pyraclostrobin	175013-18-0	099100	to Humans	(9/10/03)	NR	Not Applicable
						Hepatocellular adenomas and combined adenomas,
			Likely to be Carcinogenic to	OPP		carcinomas and/or hepatoblastomas in male and female (SPF)
Pyraflufen ethyl	129630-19-9	030090	Humans	(10/8/02)	Q1* = 3.32 E-2 (3/4)	ICR (Crj:CD-1) mice.
			Suggestive Evidence Of			Eyes Wistar Rj: WI (HOPS HAN) Rat (M); Urinary Bladder
Pyrasulfotole	365400-11-9	000692	Carcinogenic Potential	6/8/2007	NR	C57BL/6 Mouse (M & F)
			Not Likely To Be Carcinogenic			
Pyrazon	1698-60-8	069601	To Humans	7/28/2005	NR	Not Applicable
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		
Pyrethrins	8003-34-7	069001	Carcinogenic Potential	(6/22/04)	NR	Liver tumors in Crl:CD® (SD)IGS BR rats (F)
			Group EEvidence of Non-	OPP		
Pyridaben	96489-71-3	129105	carcinogenicity for Humans	(5/11/94)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Pyridalyl	179101-81-6	295149	To Humans	4/21/2009	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Pyridate	55512-33-9	128834	To Humans	1/24/2000	NR	Not Applicable
			Group CPossible Human	OPP		Thyroid follicular cell adenomas & combined adenoma/carcinoma (M); Thyroid cell adenomas (F); Sprague-
Pyrimethanil	53112-28-0	288201	Carcinogen	(2/12/97)	MOE Approach	Dawley rats.
			Group EEvidence of Non-	OPP	,,	<u> </u>
Pyriproxyfen	95737-68-1	129032	carcinogenicity for Humans	(9/15/95)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION		QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
						Liver adenomas, carcinomas & combined
						adenoma/carcinoma; CD-1 mice (M). Rare kidney tubular
			Group CPossible Human	OPP		adenomas, carcinomas & combined adenoma/ carcinoma;
Pyrithiobac-sodium	123343-16-8	078905	Carcinogen	(9/5/95)	Q1* = 1.05 E-3 (3/4)	Crl:CDBR rats (M).
			Likely To Be Carcinogenic To			Urinary Bladder Crl:CD (SD) IGS BR Rat (M); Kidney Crl:CD-1
Pyroxasulfone	447399-55-5	090099	Humans		Q1* = 5.44 E -3 (3/4)	(ICR) Mouse (M)
			Not Likely To Be Carcinogenic			
Pyroxsulam	422556-08-9	108702	To Humans	12/19/2007	NR	Not Applicable
			Group DNot Classifiable as to			
Quinchlorac	84087-01-4	128974	Human Carcinogenicity	(8/26/92)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Quinoxyfen	124495-18-7	055459	to Humans	(1/28/03)	NR	Not Applicable
			Group DNot Classifiable as to			
Quizalofop ethyl	76578-14-8	128711	Human Carcinogenicity	(3/17/88)	NR	Not Applicable
			Likely to be Carcinogenic to			Benign and malignant liver tumors in Sprague-Dawley Female
Resmethrin	10453-86-8	097801	Humans		Q1* = 5.621 E-2 (3/4)	Rat and Swiss DC-Mice (1 Male Mouse)
			Not Likely to Be Carcinogenic	OPP		
Rimsulfuron	122931-48-0	129009	to Humans	(2/19/98)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
RoteNone	83-79-4	071003	carcinogenicity for Humans	(10/5/88)	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Saflufenacil (BAS 800 H)	372137-35-4	118203	To Humans	7/22/2009	NR	Not Applicable
			Carcinogenicity, but Not	OPP		Renal tubular adenomas in male Sprague-Dawley Crl-CD-
S-Bioallethrin	28434-00-6	004004	Sufficient to Assess Human	(10/29/03)	NR	SD(BR) rats
			Not Likely to Be Carcinogenic	OPP		
Sethoxydim	74051-80-2	121001	to Humans	(3/19/03)	NR	Not Applicable
,				,		
			Not Likely to be Carcinogenic	OPP		
Simazine	122-34-9	080807	to Humans	(5/24/90)	NR	Neuroendocrine disruption MOA
			Group CPossible Human	(OPP		Liver adenomas and combined adenomas/carcinomas;
s-Metolachlor	87392-12-9	108800	Carcinogen	(11/16/94)	MOE Approach	Charles River CD (SD)BR rats (F).
			Group EEvidence Of Non-			
Sodium bentazon	50723-80-3	103901	Carcinogenicity For Humans	3/8/2006	NR	Not Applicable
			Group DNot Classifiable as to	OPP		
Sodium omadine	15922-78-8	088004	Human Carcinogenicity	(5/16/95)	NR	Not Applicable

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
	187166-40-1 +		Not Likely To Be Carcinogenic			
Spinetoram	187166-15-0	110008	To Humans	3/25/2010	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Spinosad	131929-60-7	110003	to Humans	(6/17/97)	NR	Not Applicable
						Testicular Leydig cell tumors in male Wistar rats, uterine
			Likely to be Carcinogenic to			tumors in female Wistar rats; and liver tumors in both sexes of
Spirodiclofen	148477-71-8	124871	Humans		Q1* = 1.49 E-2 (3/4)	CD-1 mice
			Not Likely To Be Carcinogenic			
Spiromesifen	283594-90-1	024875	To Humans	12/18/2008	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Spirotetramat	203313-25-1	392201	To Humans	3/26/2009	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Spiroxamine	118134-30-8	120759	to Humans	(/	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Sulfentrazone	122836-35-5	129081	carcinogenicity for Humans	(5/7/96)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Sulfosate	81591-81-3	128501	carcinogenicity for Humans	(7/26/94)	NR	Not Applicable
						Rare transitional cell papilloma & carcinoma of the urinary
						bladder in females; Sprague-Dawley rats. Rare
			Likely to be Carcinogenic to	OPP		mesenchymaltumors of the urinary bladder in male as well as
Sulfosulfuron	141776-32-1	085601	Humans		Q1* = 1.03 E-3 (3/4)	renal adenomas in male and female CD-1 mice.
			Not Likely to Be Carcinogenic	OPP		
Sulfuryl fluoride	2699-79-8	078003	to Humans	(5/24/01)	NR	Not Applicable
			Group EEvidence of Non-	OPP		
Sulprofos	35400-43-2	111501	carcinogenicity for Humans	(3/26/96)	NR	Not Applicable
			Not Likely to Be Carcinogenic			
Sumithrin	26002-80-2	069005	to Humans		NR	Not Applicable
			Not Likely To Be Carcinogenic			
Tau-fluvalinate	102851-06-9	109302	To Humans	9/29/2005	NR	Not Applicable
i au-nuvaiinate	102031-00-9	109302	Group CPossible Human	9/29/2005 OPP	INIX	Testicular interstitial cell adenomas (M); Thyroid c-cell
TCMTB (Busan 72)	21564-17-0	035603	Carcinogen	(8/28/96)	RfD Approach	adenomas (F); Sprague-Dawley rats.
TOWITD (DUSAIL 12)	21304-17-0	033003	Carcinogen	(0/20/90)	по Арргоаст	auenomas (r), Sprague-Dawiey rais.

CHEMICAL	CAS NO.	PC CODE		REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
			Group CPossible Human	OPP		Statistically significant increase in the incidence of hepatocell- ular adenomas, carcinomas & combined adenomas/carcinomas both by positive trend & pairwise
Tebuconazole	107534-96-3	128997	Carcinogen	(9/15/93)	RfD Approach	comparisons; NMRI mice (M & F).
Tebufenozide	112410-23-8	129026	Group EEvidence of Non-carcinogenicity for Humans	OPP (8/29/94)	NR	Not Applicable
T-1 (0.00 to 1	440400 77.0	000400	Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human	OPP	MD	
Tebufenpyrad	119168-77-3	090102	Carcinogenic Potential	(5/15/02)	NR	Hepatocellular adenomas in male and female F344 rats
Tebuthiuron	34014-18-1	105501	Group DNot Classifiable as to Human Carcinogenicity	(3/1/91)	NR	Not Applicable
Telone	542-75-6	029001	Group BProbable Human Carcinogen	OPP (4/15/99)	Q1* = 1.3 E-5 (3/4) (Inhalation)	Forestomach, liver, mammary, thyroid, adrenal, urinary & lung tumors; Fischer 344 rats & B6C3F1 mice (M & F). Bronchioloaveolar adenomas; B6C3F1 mice (M).
Tembotrione	335104-84-2	012801	Suggestive Evidence of Carcinogenic Potential	9/7/2007	NR	Eyes Wistar Rat (M)
Tepraloxydim	149979-41-9	121005	Data Are Inadequate for an Assessment of Human Carcinogenic Potential	OPP (2/26/01)	NR	Not Applicable
Terbacil	5902-51-2	012701	Group EEvidence of Non-carcinogenicity for Humans	OPP (9/30/94)	NR	Not Applicable
Terbufos	13071-79-9	105001	Group EEvidence of Non-carcinogenicity for Humans	OPP (2/1/94)	NR	Not Applicable
Terbuthylazine	5915-41-3	080814	Group DNot Classifiable as to Human Carcinogenicity	OPP (8/24/94)	NR	Not Applicable
Terbutryn	886-50-0	080813	Group CPossible Human Carcinogen	OPP (3/3/88)	NR	Mammary (adenomas/adenocarcinomas) and Liver (adenomas/carcinomas) in female CD rats; Thyroid follicular (adenomas/carcinomas)and Testicular interstitial cell adenomas in male CD rats.
			Group BProbable Human	OPP	2.4. 2.2. 2.4.13	Multiple tumors (liver, bile duct, mammary gland, thyroid & testes) & cholangiocarcinoma (a rare tumor); Sprague-Dawley
Terrazole	2593-15-9	084701	Carcinogen	(1/9/91)	Q1* = 3.33 E-2 (3/4)	rats (M & F).

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
						Hepatocellular carcinomas & combined
						adenomas/carcinomas; B6C3F1 mice (F). Thyroid C-cell
			Likely to be Carcinogenic to	OPP		adenomas & adrenal pheochromocytomas; Sprague-Dawley
Tetrachlorvinphos	961-11-5	083701	Humans	(3/7/02)	Q1* = 1.83 E-3 (3/4)	rats (M).
			Likely to be Carcinogenic to	OPP		Hepatocellular adenomas, carcinomas and combined
Tetraconazole	112281-77-3	120603	Humans	(1/11/00)	Q1* = 2.3 E-2 (3/4)	adenomas/carcinomas in both sexes; Crl:CD-1 (ICR) mice
			Group CPossible Human	OPP		Interstitial cell adenomas in the testes (M); CR CD-1 & CRCD
Tetramethrin	7696-12-0	069003	Carcinogen	(12/11/89)	NR	Sprague-Dawley, Long-Evans Hooded rats.
			Multiple Descriptors: Likely to			
			be Carcinogenic to Humans at			
			High Does; Not Likely to be			Thyroid follicular cell adenomas and combined
			Carcinogenic to Humans at	OPP		adenomas/carcinomas in M&F Sprague-Dawley Crl:CD BR
Thiabendazole	148-79-8	060101	Low Doses	(3/8/02)	MOE Approach	rats
						Thyoid follicular cell adenomas in male Wistar rats; uterine
						adenomas, adenocarcinomas and/or adenosquamous
			Likely to be Carcinogenic to	OPP		carcinomas in female Wistar rats; ovarian luteomas in female
Thiacloprid	111988-49-9	014019	Humans	(3/26/03)	Q1* = 4.06 E-2 (3/4)	B6C3F mice.
			Not Likely to Be Carcinogenic	OPP		
Thiamethoxam	153719-23-4	060109	to Humans	(6/20/00)	NR	Liver tumors in mice
						Statistically significant increase in thyroid follicular cell tumors
						(M). Increases in renal tubular adenomas (M & F); however
			Group CPossible Human	OPP		statisti- cally significant positive trend in F only; Sprague-
Thiazopyr (MON 13200)	117718-60-2	129100	Carcinogen	(5/25/94)	MOE Approach	Dawley rats.
			Not Likely To Be Carcinogenic			
Thidiazuron	51707-55-2	120301	To Humans	8/31/2005	NR	Not Applicable
			Not Likely To Be Carcinogenic			
			To Humans at doses that do			
			not cause urothelium			
Thiencarbazone-methyl	317815-83-1	015804	cytotoxicity	6/25/2008	NR	Not Applicable
			Not Likely To Be Carcinogenic			
Thifensulfuron methyl	79277-27-1	128845	To Humans	1/29/2010	NR	Not Applicable
			Group DNot Classifiable as to			
Thiobencarb (Bolero)	28249-77-6	108401	Human Carcinogenicity	(6/10/96)	NR	Not Applicable
			Group DNot Classifiable as to			
Thiocyclam hydrogen oxalate	31895-22-4	128868	Human Carcinogenicity	(9/15/94)	NR	Not Applicable
			Group BProbable Human	OPP		Liver tumors (malignant & benign); CD-1 mice (M & F).
Thiodicarb	59669-26-0	114501	Carcinogen	(6/10/96)	MOE Approach	Testicular interstitial cell tumors; Sprague-Dawley rat (M).

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT DATE	QUANTIFICATION METHOD	TUMOR SITES/ STRAIN/ SPECIES/ SEX
						Hepatocellular adenomas (M & F); Combined adenomas, carcinomas and/or hepatoblastomas (M); CD-1 mice. Thyroid follicular cell adenomas (M & F); Thyroid follicular cell
			Likely to be Carcinogenic to	OPP		carcinomas as well as combined adenomas and/or carcinomas
Thiophanate-methyl	23564-05-8	102001	Humans	(12/8/01)	Q1* = 1.16 E-2 (3/4)	(M); F344 rats.
,			Not Likely to Be Carcinogenic	OPP		
Thiram	137-26-8	079801	to Humans	(4/14/03)	NR	Not Applicable
			Likely to be Carcinogenic to	OPP		
Tolyfluanid	731-27-1	309200	Humans	(5/01/02)	Q1* = 1.59 E-3 (3/4)	Thyroid tumors in male and female Wistar rats.
Topramezone	210631-68-8	123009	Multiple Descriptors: Not Likely to be Carcinogenic to Humans at Doses that Do Not Alter Rat Thyroid Hormone Homeostasis		NR	Thyroid follicular cell in both sexes of Wistar rats; Anti-thyroid MOA
Tralkoxydim	87820-88-0	121000	Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential	OPP (6/30/04)	NR	Benign testicular tumors in male rats and equivocal evidence of benign sex cord stromal tumors in female hamsters.
Triadimefon	43121-43-3	109901	Group CPossible Human Carcinogen	OPP (12/4/96)	RfD Approach	Borderline statistically significant increase thyroid adenomas; Wistar rats (M). Hepatocelular adenomas; NMRI mice (M & F).
			Group CPossible Human	OPP		
Triadimenol	55219-65-3	127201	Carcinogen	(1/29/88)	NR	Liver (hepatocellular adenomas); CF1/W74 mice (F).
Triallate	2303-17-5	078802	Group CPossible Human Carcinogen	OPP (1/12/94)	Q1* = 7.17 E-2 (3/4)	Hepatocellular carcinomas (M); Positive trend & a boderline signifi- cant increase in these tumors in females; B6C3F1 mice. Increased incidence of renal tubular cell adenoma (rare tumor type); Sprague-Dawley rat (M)
			Group EEvidence of Non-	OPP	,	, , , , , , , , , , , , , , , , , , ,
Triasulfuron	82097-50-5	128969	carcinogenicity for Humans	(3/11/91)	NR	Not Applicable
			Not Likely to Be Carcinogenic	OPP		
Triazamate	112143-82-5	128100	to Humans	(12/1/97)	NR	Not Applicable
Tribenuron methyl	101200-48-0	128887	Group CPossible Human Carcinogen	OPP (7/14/89)	NR	Mammary gland adenocarcinomas; Sprague-Dawley rats (F).
Tribufos	78-48-8	074801	be Carcinogenic to Humans (High Doses); Not Likely to be Carcinogenic to Humans (Low	OPP (5/22/97)	MOE Approach	Liver (hemangiosarcoma) (M), Lung (alveolar/bronchiolar adenoma) (F), Small intestine (adenocarcinoma) (M & F); CD-1 mice.

Tributyltin maleate (oxide) 14275-57-1 O83118 Cannot Be Determined Group DNot Classifiable As To Human Carcinogenicity Multiple Descriptors: Likely to be Carcinogenic to Humans (High Doses), Not Likely to be Carcinogenic to Humans (Low Doses) Trichlorfon 52-68-6 O57901 O52901 Triclopyr Triclopyr 55335-06-3 116001 Triclosan 3380-34-5 O54901 Tridiphane 58138-08-2 123901 Trifloxystrobin DATE METHOD Not Applicable	
Tributyltin maleate (oxide) 14275-57-1 083118 DNot Classifiable As To Human Carcinogenicity Multiple Descriptors: Likely to be Carcinogenic to Humans (High Doses), Not Likely to be Carcinogenic to Humans (Low Carcinomas in F). Mammary tumors in female Carcinomas in F). Mammary tumors in female Carcinogenic Triclopyr Triclopyr 55335-06-3 116001 Triclosan 3380-34-5 054901 To Humans Group CPossible Human Tridliphane 58138-08-2 123901 Carcinogen Not Likely to Be Carcinogenic (4/22/86) Not Likely to Be Carcinogenic (4/22/86) Not Likely to Be Carcinogenic (6/16/99) Not Applicable Not Applicable	
Tributyltin maleate (oxide) 14275-57-1 083118 Human Carcinogenicity Multiple Descriptors: Likely to be Carcinogenic to Humans (High Doses), Not Likely to be Carcinogenic to Humans (Low Carcinogenic to Human Carcinogenic to Human Carcinogenic to Human Carcinogenic (5/8/96) Triclopyr 55335-06-3 116001 Human Carcinogenicity Friclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP Liver (hepatocellular adenomas, adenomas/carcinogenic (4/22/86)) Not Likely to Be Carcinogenic Not Likely to Be Carcinogenic Not Likely to Be Carcinogenic OPP Trifloxystrobin 141517-21-7 129112 Tributyltin maleate (oxide) Multiple Descriptors: Likely to be Carcinogenic to Humans OPP Liver (hepatocellular adenomas, adenomas/carcinogenic (4/22/86)) NR Not Applicable	
Multiple Descriptors: Likely to be Carcinogenic to Humans (High Doses), Not Likely to be Carcinogenic to Humans (Low Carcinogenic to Humans (Low Doses) Trichlorfon 52-68-6 057901 Doses) Trichlorfon 52-68-6 057901 Doses) Triclopyr 55335-06-3 116001 Human Carcinogenicity (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans (DP) Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR Liver CD-1 Mouse (M & F) Trifloxystrobin 141517-21-7 129112 to Humans (OPP) Trifloxystrobin Not Likely to Be Carcinogenic (4/22/86) NR Not Applicable Tumors of the kidneys (adenomas) in male F34 of the lungs in both sexes (adenomas/carcinome (7/15/99) NR carcinomas in F). Mammary tumors in female C OPP Tumors of the kidneys (adenomas) in male F34 of the lungs in both sexes (adenomas/carcinome (7/15/99) NR Not Applicable	
be Carcinogenic to Humans (High Doses), Not Likely to be Carcinogenic to Humans (Low DOPP (7/15/99) NR carcinomas in F). Mammary tumors in female C Group DNot Classifiable as to DOPP (5/8/96) NR Not Applicable Triclopyr 55335-06-3 116001 Human Carcinogenicity (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human Carcinogenic (4/22/86) NR Combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
(High Doses), Not Likely to be Carcinogenic to Humans (Low OPP OF Carcinogenic to Human Carcinogenic Triclopyr OPP OF Carcinogenic To Humans OPP OPP OPP OPP OPP OPP OPP OPP OPP OP	
Carcinogenic to Humans (Low DPP (7/15/99) NR carcinomas in F). Mammary tumors in female C Group DNot Classifiable as to DPP (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans (DPP (5/8/96) NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP (4/22/86) NR Combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (DPP (6/16/99) NR Not Applicable	4 rats & tumors
Trichlorfon 52-68-6 057901 Doses) (7/15/99) NR carcinomas in F). Mammary tumors in female C Group DNot Classifiable as to OPP Triclopyr 55335-06-3 116001 Human Carcinogenicity (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Triclopyr 55335-06-3 116001 Human Carcinogenicity (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP Liver (hepatocellular adenomas, adenomas/carc (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Triclopyr 55335-06-3 116001 Human Carcinogenicity (5/8/96) NR Not Applicable Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Group CPossible Human OPP Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Triclosan 3380-34-5 054901 To Humans 10/22/1998 NR Liver CD-1 Mouse (M & F) Tridiphane Group CPossible Human OPP Liver (hepatocellular adenomas, adenomas/card (4/22/86) Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Tridiphane 58138-08-2 123901 Carcinogen (4/22/86) NR combined); B6C3F1 mice (F). Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	cinomas
Trifloxystrobin 141517-21-7 129112 to Humans OPP (6/16/99) NR Not Applicable	omornao
Trifloxystrobin 141517-21-7 129112 to Humans (6/16/99) NR Not Applicable	
Not Likely to Be Carcinogenic OPP	
Trifloxysulfuron 290332-10-4 119009 to Humans (7/22/03) NR Not Applicable	
Group EEvidence of Non- OPP	
Triflumizole 68694-11-1 128879 carcinogenicity for Humans (8/10/93) NR Not Applicable	
Thyroid (follicular cell adenomas & carcinomas)	; Neoplasms of
Group CPossible Human OPP the renal pelvis (M); Benign urinary bladder tum	
Trifluralin 1582-09-8 036101 Carcinogen (4/11/86) Q1* = 2.93 E-3 (3/4) 344 rats.	. , ,
Group CPossible Human OPP	
Triflusulfuron-methyl 126535-15-7 129002 Carcinogen (5/28/96) RfD Approach Testicular interstitial cell adenomas; CD-1 rat (N	Л).
Suggestive Evidence of	
Carcinogenicity, but Not	
Sufficient to Assess Human OPP Liver tumors in male mice and lung tumors in fe	male mice only
Triforine 26644-46-2 107901 Carcinogenic Potential (6/29/04) NR at the limit dose.	-
Not Likely To Be Carcinogenic	
Trinexapac-Ethyl 95266-40-3 112602 To Humans 9/5/2008 NR Not Applicable	
Pituitary gland adenoma (F); Leydig cell tumors	(M); Wistar
Group BProbable Human OPP rat. Hepatocellular adenomas (M & F); combine	
Triphenyltin hydroxide (TPTH) 76-87-9 083601 Carcinogen (5/24/90) Q1* = 1.83 E-0 (3/4) (adenomas and/or carcinoma) (F); NMRI mice.	·
Not Likely to be Carcinogenic	
Triticonazole 131983-72-7 125620 to Humans NR Not Applicable	

CHEMICAL	CAS NO.	PC CODE	CANCER CLASSIFICATION	REPORT	QUANTIFICATION	TUMOR SITES/ STRAIN/ SPECIES/ SEX
				DATE	METHOD	
			Not Likely to Be Carcinogenic	OPP		
Troysan polyphase (IPBC)	55406-53-6	107801	to Humans	(12/4/96)	NR	Not Applicable
			Group BProbable Human	OPP		Multiple sites (eg. lungs, vessels, liver & kidney); Multiple
UDMH	57-14-7	600018	Carcinogen	(7/26/91)	Q1* = 4.6 E-1 (2/3)	species, strains & studies.
			Group EEvidence of Non-	OPP		
UMP-488 (PAL 6000)	111578-32-6	129025	carcinogenicity for Humans	(5/6/94)	NR	Not Applicable
			Group CPossible Human	OPP		Hepatocellular adenomas, carcinomas &
Uniconazole	83657-22-1	128976	Carcinogen	(10/11/90)	NR	adenomas/carcinomas combined; CD-1 mice (M).
			Group CPossible Human	OPP		
Vinclozolin	50471-44-8	113201	Carcinogen	(6/20/00)	MOE Approach	Leydig cell adenomas; Wistar rats (M)
						Benign lung adenomas (increase in both adenomas and
			Group CPossible Human	OPP		adenomas/ carcinomas combined); Alderly Park SPF Swiss
Zeta-Cypermethrin	52315-07-8	129064	Carcinogen	(9/27/88)	NR	strain mice (F).
			Suggestive Evidence of			
			Carcinogenicity, but Not			
			Sufficient to Assess Human	OPP		Hemangiomas in male CD(SD)BR rats; increasing trend in
Ziram	137-30-4	034805	Carcinogenic Potential	(2/6/03)	NR	preputial gland adenomas in male F344 rats
			Not Likely to Be Carcinogenic	OPP		
Zoxamide	156052-68-5	101702	to Humans	(12/16/99)	NR	Not Applicable